Sources

1045 sources

Law (95)

Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 1, § 1, 1) (definitie van geneesmiddel). ejustice.just.fgov.be (Justel; text updated to 4 June 2026). Law ejustice.just.fgov.be (opens an external site) — accessed 22 October 2026
Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 6quater (uitzonderingen op de VHB-plicht). ejustice.just.fgov.be (Justel; text updated to 4 June 2026). Law ejustice.just.fgov.be (opens an external site) — accessed 22 October 2026
Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 9 (reclame). ejustice.just.fgov.be (Justel; text updated to 4 June 2026). Law ejustice.just.fgov.be (opens an external site) — accessed 22 October 2026
Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 12quater (geneesmiddelen voor eigen gebruik uit een andere lidstaat). ejustice.just.fgov.be (Justel; text updated to 4 June 2026). Law ejustice.just.fgov.be (opens an external site) — accessed 22 October 2026
Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 16 (straffen). ejustice.just.fgov.be (Justel; text updated to 4 June 2026). Law ejustice.just.fgov.be (opens an external site) — accessed 22 October 2026
Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 6 § 1 (vergunning voor het in de handel brengen vereist). ejustice.just.fgov.be. Law ejustice.just.fgov.be (opens an external site) — accessed 20 October 2026
Bundeskanzleramt (2025). Bekanntmachung der Neufassung der Anlage I zu dem Internationalen Übereinkommen vom 19. Oktober 2005 gegen Doping im Sport / des Anhangs zu dem Übereinkommen vom 16. November 1989 gegen Doping, vom 18. Dezember 2025. Bundesgesetzblatt 2025 Teil II Nr. 312 (23 December 2025). Law recht.bund.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2015). Anti-Doping-Gesetz (AntiDopG), § 6 Verordnungsermächtigungen. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2023). Anti-Doping-Gesetz (AntiDopG), § 3 Selbstdoping. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2023). Anti-Doping-Gesetz (AntiDopG), § 4 Strafvorschriften. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2023). Gesetz gegen Doping im Sport (Anti-Doping-Gesetz – AntiDopG), Anlage (zu § 2 Absatz 3). gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 20 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 21 Zulassungspflicht. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 20 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 2 Arzneimittelbegriff. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 4 Sonstige Begriffsbestimmungen. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 5 Verbot bedenklicher Arzneimittel. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 8 Verbote zum Schutz vor Täuschung. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 73 Verbringungsverbot. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 95 Strafvorschriften. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 96 Strafvorschriften. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 97 Bußgeldvorschriften. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Heilmittelwerbegesetz (HWG), § 3a. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Heilmittelwerbegesetz (HWG), § 10. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Heilmittelwerbegesetz (HWG), § 15 (Ordnungswidrigkeiten). gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Bundesministerium der Justiz (2026). Gesetz gegen Doping im Sport (Anti-Doping-Gesetz – AntiDopG), § 2 Unerlaubter Umgang mit Dopingmitteln. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 20 October 2026
Bundesministerium der Justiz (2026). Sozialgesetzbuch (SGB) Fünftes Buch (V) — § 34 Ausgeschlossene Arznei-, Heil- und Hilfsmittel. gesetze-im-internet.de. Law gesetze-im-internet.de (opens an external site) — accessed 20 October 2026
Bundesministerium für Gesundheit (2023). Verordnung zur Festlegung der nicht geringen Menge von Dopingmitteln (Dopingmittel-Mengen-Verordnung – DmMV) vom 10. März 2023. gesetze-im-internet.de (BGBl. 2023 I Nr. 67, S. 5). Law gesetze-im-internet.de (opens an external site) — accessed 22 October 2026
Council of the European Communities (1993). Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. Official Journal of the European Communities, L 214, 24 August 1993, pp. 1-21. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Council of the European Economic Community (1965). Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. Official Journal of the European Communities, 022, 9 February 1965, pp. 369-373. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Court of Justice of the European Communities (Fifth Chamber) (1983). Judgment of 30 November 1983, Criminal proceedings against Leendert van Bennekom, Case 227/82. EUR-Lex (CELEX 61982CJ0227). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Court of Justice of the European Communities (First Chamber) (2009). Judgment of 15 January 2009, Hecht-Pharma GmbH v Staatliches Gewerbeaufsichtsamt Lüneburg, Case C-140/07. EUR-Lex (CELEX 62007CJ0140). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Court of Justice of the European Communities (Second Chamber) (2009). Judgment of 2 April 2009, Criminal proceedings against Frede Damgaard, Case C-421/07. EUR-Lex (CELEX 62007CJ0421). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Court of Justice of the European Union (Fourth Chamber) (2014). Judgment of 10 July 2014, Criminal proceedings against Markus D. and G., Joined Cases C-358/13 and C-181/14. EUR-Lex (CELEX 62013CJ0358). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Court of Justice of the European Union (Third Chamber) (2012). Judgment of 29 March 2012, European Commission v Republic of Poland, Case C-185/10. EUR-Lex (CELEX 62010CJ0185). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Court of Justice of the European Union (Third Chamber) (2015). Judgment of 16 July 2015, Abcur AB v Apoteket Farmaci AB and Apoteket AB, Joined Cases C-544/13 and C-545/13. EUR-Lex (CELEX 62013CJ0544). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
European Commission (2014). Commission Implementing Regulation (EU) No 699/2014 of 24 June 2014 on the design of the common logo to identify persons offering medicinal products for sale at a distance to the public and the technical, electronic and cryptographic requirements for verification of its authenticity. Official Journal of the European Union, L 184, 25 June 2014. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
European Commission (2016). Commission Delegated Regulation (EU) 2016/161 supplementing Directive 2001/83/EC by laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use. Official Journal of the European Union, L 32. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
European Commission (2020). Commission Implementing Regulation (EU) 2020/16 of 10 January 2020 authorising the placing on the market of nicotinamide riboside chloride as a novel food under Regulation (EU) 2015/2283 and amending Implementing Regulation (EU) 2017/2470. Official Journal of the European Union, L 7, 13.1.2020, p. 6. Law eur-lex.europa.eu (opens an external site) — accessed 23 October 2026
European Commission (2026). Commission Implementing Regulation (EU) 2017/2470 establishing the Union list of novel foods, consolidated text of 10 August 2026. EUR-Lex, CELEX 02017R2470-20260810. Law eur-lex.europa.eu (opens an external site) — accessed 23 October 2026
European Parliament and Council of the European Union (2001). Directive 2001/83/EC of 6 November 2001 on the Community code relating to medicinal products for human use (text as adopted). Official Journal of the European Communities, L 311, 28 November 2001, pp. 67-128. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
European Parliament and Council of the European Union (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text). Official Journal of the European Communities, L 311. Law eur-lex.europa.eu (opens an external site) — accessed 20 October 2026
European Parliament and Council of the European Union (2002). Regulation (EC) No 178/2002 laying down the general principles and requirements of food law, Article 2 (definition of food). Official Journal of the European Communities, L 31. Law eur-lex.europa.eu (opens an external site) — accessed 23 October 2026
European Parliament and Council of the European Union (2004). Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (consolidated text of 28 January 2022). Official Journal of the European Union, L 136. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
European Parliament and Council of the European Union (2009). Regulation (EC) No 1223/2009 on cosmetic products, Article 2 (definitions). Official Journal of the European Union, L 342. Law eur-lex.europa.eu (opens an external site) — accessed 23 October 2026
European Parliament and Council of the European Union (2011). Directive 2011/62/EU amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of falsified medicinal products. Official Journal of the European Union, L 174. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
European Parliament and Council of the European Union (2014). Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. Official Journal of the European Union, L 158. Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026
Koninkrijk der Nederlanden (1958). Wet van 28 juli 1958, houdende nieuwe regelen nopens de geneesmiddelenvoorziening en de uitoefening der artsenijbereidkunst (Wet op de geneesmiddelenvoorziening), Stb. 1958, 408. Staatsblad van het Koninkrijk der Nederlanden. Law repository.overheid.nl (opens an external site) — accessed 22 October 2026
Legal Information Institute, Cornell Law School (text of the United States Code) (2026). 21 U.S. Code § 321 – Definitions (FD&C Act § 201). United States Code. Law law.cornell.edu (opens an external site) — accessed 22 October 2026
Legal Information Institute, Cornell Law School (text of the United States Code) (2026). 21 U.S. Code § 355 – New drugs (FD&C Act § 505). United States Code. Law law.cornell.edu (opens an external site) — accessed 22 October 2026
Legal Information Institute, Cornell Law School (text of the United States Code) (2026). 21 U.S. Code § 353a – Pharmacy compounding (FD&C Act § 503A). United States Code. Law law.cornell.edu (opens an external site) — accessed 22 October 2026
Legal Information Institute, Cornell Law School (text of the United States Code) (2026). 21 U.S. Code § 353b – Outsourcing facilities (FD&C Act § 503B). United States Code. Law law.cornell.edu (opens an external site) — accessed 22 October 2026
Legal Information Institute, Cornell Law School (text of the United States Code) (2026). 21 U.S. Code § 381 – Imports and exports (FD&C Act § 801). United States Code. Law law.cornell.edu (opens an external site) — accessed 22 October 2026
Legal Information Institute, Cornell Law School (text of the United States Code) (2026). 21 U.S. Code § 333 – Penalties (FD&C Act § 303). United States Code. Law law.cornell.edu (opens an external site) — accessed 22 October 2026
Minister van Volksgezondheid, Welzijn en Sport (2007). Regeling Geneesmiddelenwet, artikelen 3.17, 3.17a en 3.18 (ontheffing op artsenverklaring; vrijstelling bij tekort; gebruik in schrijnende gevallen). wetten.overheid.nl (BWBR0022160), version in force from 1 January 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1950). Wet op de economische delicten, artikelen 1, 2 en 6. wetten.overheid.nl (BWBR0002063), version in force from 22 September 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1993). Wet op de beroepen in de individuele gezondheidszorg (Wet BIG), artikelen 35 en 36 (voorbehouden handelingen). wetten.overheid.nl (BWBR0006251), version in force from 5 July 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1994). Burgerlijk Wetboek Boek 7, artikel 448 (WGBO: de arts licht de patiënt in). wetten.overheid.nl (BWBR0005290), version in force from 8 October 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1994). Burgerlijk Wetboek Boek 7, artikel 450 (WGBO: toestemming van de patiënt). wetten.overheid.nl (BWBR0005290), version in force from 8 October 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1994). Burgerlijk Wetboek Boek 7, artikel 452 (WGBO: de patiënt geeft de nodige inlichtingen). wetten.overheid.nl (BWBR0005290), version in force from 8 October 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1994). Burgerlijk Wetboek Boek 7, artikel 453 (WGBO: zorg van een goed hulpverlener). wetten.overheid.nl (BWBR0005290), version in force from 8 October 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1994). Burgerlijk Wetboek Boek 7, artikelen 454-456 (WGBO: het medisch dossier, eigen verklaring, inzage en afschrift). wetten.overheid.nl (BWBR0005290), version in force from 8 October 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1994). Burgerlijk Wetboek Boek 7, artikel 457 (WGBO: geheimhouding). wetten.overheid.nl (BWBR0005290), version in force from 8 October 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (1998). Telecommunicatiewet, artikel 11.7a (opslaan van of toegang tot informatie in de randapparatuur van een gebruiker). wetten.overheid.nl (BWBR0009950), version in force from 15 August 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 1, eerste lid, onder b (definitie van geneesmiddel). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 40 (verbod op geneesmiddelen zonder handelsvergunning, en de uitzonderingen). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 61 (wie UR-geneesmiddelen mag afleveren; geen aflevering zonder recept). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 67 (geen recepten via internet voor onbekende patiënten). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 68 (voorschrijven buiten de geregistreerde indicaties). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet (BWBR0021505), version in force from 1 July 2007. wetten.overheid.nl. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 1, eerste lid, onder hh, xx en ijij (invoeren, reclame, publieksreclame). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 18 (vergunning voor bereiden, invoeren en groothandel). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 67a (verkoop op afstand). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikelen 84 en 85 (reclame; publieksreclame). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 100 (toezicht: IGJ en NVWA). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 101 (bestuurlijke boete). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 115 (inbeslagname en bevelen). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026
Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet (BWBR0021505). wetten.overheid.nl. Law wetten.overheid.nl (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (Code of Federal Regulations) (2002). 21 CFR 314.126 Adequate and well-controlled studies. Electronic Code of Federal Regulations. Law ecfr.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (Electronic Code of Federal Regulations) (2019). 21 CFR 216.23 – Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. eCFR. Law ecfr.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (Electronic Code of Federal Regulations) (2026). 21 CFR 600.3 – Definitions, paragraph (h)(6): 'protein'. eCFR. Law ecfr.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (Electronic Code of Federal Regulations) (2026). 21 CFR 201.128 – Meaning of 'intended uses'. eCFR. Law ecfr.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (Electronic Code of Federal Regulations) (2026). 21 CFR 809.10 – Labeling for in vitro diagnostic products. eCFR. Law ecfr.gov (opens an external site) — accessed 22 October 2026
UK Parliament (1971). Misuse of Drugs Act 1971, Schedule 2 (Controlled drugs), Part III: Class C drugs. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 46: Requirement for authorisation. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 20 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 2: Medicinal products. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 17: Manufacturing of medicinal products. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 47: Offences in connection with authorisation. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 167: Supply to fulfil special patient needs. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 214: Sale or supply of prescription only medicines. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 255: Offences under Part 12. legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 279: Requirement for authorisation (advertising). legislation.gov.uk. Law legislation.gov.uk (opens an external site) — accessed 22 October 2026
United States Congress (1938). Federal Food, Drug, and Cosmetic Act, Public No. 717 (75th Congress), chapter 675, 52 Stat. 1040, approved 25 June 1938. United States Statutes at Large, volume 52. Law govinfo.gov (opens an external site) — accessed 22 October 2026
United States Congress (1962). Public Law 87-781 (Drug Amendments of 1962), 76 Stat. 780, approved 10 October 1962. United States Statutes at Large, volume 76. Law govinfo.gov (opens an external site) — accessed 22 October 2026
Vlaamse Gemeenschap (2012). Decreet van 25 mei 2012 betreffende de preventie en bestrijding van doping in de sport. Belgisch Staatsblad, 12 July 2012, p. 38313 (original text, as published by NADO Vlaanderen). Law dopinglijn.be (opens an external site) — accessed 22 October 2026
Zorginstituut Nederland (2026). Regeling zorgverzekering, bijlage 2 (as reproduced in the Farmacotherapeutisch Kompas) — item 146: dulaglutide en semaglutide. Farmacotherapeutisch Kompas. Law farmacotherapeutischkompas.nl (opens an external site) — accessed 20 October 2026
Zorginstituut Nederland (2026). Regeling zorgverzekering, bijlage 2 (as reproduced in the Farmacotherapeutisch Kompas) — item 194: tirzepatide. Farmacotherapeutisch Kompas. Law farmacotherapeutischkompas.nl (opens an external site) — accessed 20 October 2026

Regulator (199)

Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (2010). Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) warnt vor Anwendung melanotanhaltiger Produkte für kosmetische Zwecke (Pressemitteilung 14/10). Regulator bfarm.de (opens an external site) — accessed 22 October 2026
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (2024). Fälschung des Arzneimittels Ozempic® (updates 11.10.2023 – 15.02.2024). Regulator bfarm.de (opens an external site) — accessed 20 October 2026
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (2026). Nebenwirkungen und weitere Arzneimittelrisiken melden. Regulator bfarm.de (opens an external site) — accessed 22 October 2026
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (2026). Arzneimittelfälschungen. Regulator bfarm.de (opens an external site) — accessed 22 October 2026
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (2026). Archiv Lieferengpässe — GLP-1-Rezeptor-Agonisten. Regulator bfarm.de (opens an external site) — accessed 20 October 2026
Bundesministerium für Gesundheit (gesund.bund.de) (2022). Numbers to call in the event of an emergency. Regulator gesund.bund.de (opens an external site) — accessed 22 October 2026
Bundesministerium für Gesundheit (gesund.bund.de) (2026). Umgang mit Arzneimitteln: Richtig lagern, einnehmen und entsorgen. Regulator gesund.bund.de (opens an external site) — accessed 20 October 2026
Centers for Disease Control and Prevention (2024). Preventing Unsafe Injection Practices. Regulator cdc.gov (opens an external site) — accessed 20 October 2026
Centers for Disease Control and Prevention (2024). Safe Injection Practices to Prevent Transmission of Infections to Patients. Regulator cdc.gov (opens an external site) — accessed 20 October 2026
Centers for Medicare & Medicaid Services (2026). What is Open Payments?. Regulator cms.gov (opens an external site) — accessed 22 October 2026
Centrale Commissie Mensgebonden Onderzoek (CCMO) (2026). Achtergrondinformatie over meedoen aan onderzoek. Regulator ccmo.nl (opens an external site) — accessed 22 October 2026
Centrale Commissie Mensgebonden Onderzoek (CCMO) (2026). Algemene informatie over meedoen aan onderzoek (IVO). Regulator ccmo.nl (opens an external site) — accessed 22 October 2026
College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2023). CBG waarschuwt voor aanhoudend tekort diabetesmedicijn Ozempic (news item with updates 2023–2025). Regulator cbg-meb.nl (opens an external site) — accessed 20 October 2026
College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2024). Aanbevelingen om tekorten GLP-1 receptor agonisten te beperken. Regulator cbg-meb.nl (opens an external site) — accessed 20 October 2026
College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2026). Compassionate use programma. Regulator cbg-meb.nl (opens an external site) — accessed 22 October 2026
College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2026). Overzicht van goedgekeurde compassionate use programma's. Regulator cbg-meb.nl (opens an external site) — accessed 20 October 2026
College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2026). Standpunt: Gebruik diabetes- en afslankmedicijnen alleen zoals ze bedoeld zijn. Regulator cbg-meb.nl (opens an external site) — accessed 20 October 2026
College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2026). Geneesmiddeleninformatiebank (database of medicines authorised in the Netherlands). Regulator geneesmiddeleninformatiebank.nl (opens an external site) — accessed 20 October 2026
Department of Health, Victoria (Australia), Chief Health Officer (2026). Toxicity linked to unapproved peptide product labelled Retatrutide (health alert). Regulator health.vic.gov.au (opens an external site) — accessed 22 October 2026
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, et al. (2026). Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC. EFSA Journal 24:e10007. Regulator doi:10.2903/j.efsa.2026.10007 (opens an external site)
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Castenmiller J, et al. (2021). Extension of use of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 19:e06843. Regulator doi:10.2903/j.efsa.2021.6843 (opens an external site)
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Castenmiller J, de Henauw S, et al. (2019). Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA Journal 17:e05775. Regulator doi:10.2903/j.efsa.2019.5775 (opens an external site)
European Commission (2026). 112: the European emergency number. Regulator digital-strategy.ec.europa.eu (opens an external site) — accessed 20 October 2026
European Commission, DG Internal Market, Industry, Entrepreneurship and SMEs (2026). CosIng – Cosmetic ingredient database: COPPER TRIPEPTIDE-1 (substance ID 55687). Regulator ec.europa.eu (opens an external site) — accessed 23 October 2026
European Commission, Directorate-General for Health and Food Safety (2015). 50 years of EU pharmaceutical legislation: milestones (timeline). Regulator ec.europa.eu (opens an external site) — accessed 22 October 2026
European Commission, Directorate-General for Health and Food Safety (2026). Legal framework governing medicinal products for human use in the EU. Regulator health.ec.europa.eu (opens an external site) — accessed 22 October 2026
European Commission, Directorate-General for Health and Food Safety (2026). EudraLex – Volume 4 – Good Manufacturing Practice (GMP) guidelines. Regulator health.ec.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2003). EU/3/02/110 – orphan designation for treatment of hepatocellular carcinoma (thymalfasin). Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2012). Egrifta: withdrawal of the marketing authorisation application (EMEA/H/C/002427), with questions and answers (EMA/CHMP/475021/2012). Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2017). Adlumiz (anamorelin): refusal of marketing authorisation. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2021). Repurposing of authorised medicines: pilot to support not-for-profit organisations and academia. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2023). EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens. Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2024). Ghryvelin (previously Macimorelin Aeterna Zentaris): EPAR – medicine overview. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2024). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2024). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 July 2024. Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2024). EU/3/21/2430 – orphan designation for treatment of Barth syndrome (elamipretide). Regulator ema.europa.eu (opens an external site) — accessed 23 October 2026
European Medicines Agency (2024). Outcome of assessment on use of Mounjaro in treatment of obstructive sleep apnoea (EMA/576853/2024). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2025). PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Conditional marketing authorisation. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). New oral GLP-1 medicine for weight management and type 2 diabetes. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Foundayo (orforglipron): opinion page (EMEA/H/C/006632). Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). History of EMA. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Accelerated assessment. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). PRIME: priority medicines. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Compassionate use. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Clinical Trials Regulation. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Reform of the EU pharmaceutical legislation. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Applications for new human medicines under evaluation by the CHMP: October 2026. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Applications for new human medicines under evaluation by the CHMP — October 2026 (EMA/222468/2026). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Wegovy: EPAR — procedural steps taken and scientific information after authorisation. Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). First oral GLP-1 treatment for weight management. Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Medicines (search of centrally authorised medicines and EPARs). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Mounjaro: EPAR — procedural steps taken and scientific information after authorisation. Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Mounjaro: EPAR — procedural steps taken and scientific information after authorisation (archive). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Outcome of assessment on use of Mounjaro in treatment of heart failure with preserved ejection fraction in adults with obesity (EMA/18704/2026). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Outcome of assessment on use of Mounjaro to reduce the risk of serious events affecting the heart and blood circulation (EMA/140483/2026). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (ICH) (2000). ICH Q7 Good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00). European Medicines Agency, scientific guideline. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency, CHMP and CVMP (2025). Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). European Medicines Agency. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency, Committee for Medicinal Products for Human Use (2017). Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1). Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG) (2013). Nagemaakte en illegale geneesmiddelen: opgepast! (Melanotan). Regulator fagg-afmps.be (opens an external site) — accessed 22 October 2026
Federal Agency for Medicines and Health Products (FAMHP / FAGG / AFMPS) (2023). Questions and answers regarding reporting adverse reactions. Regulator famhp.be (opens an external site) — accessed 22 October 2026
Federal Agency for Medicines and Health Products (FAMHP / FAGG / AFMPS) (2024). Questions and answers on seizure of postal packages due to illegal importation of medicinal products or importation of non-compliant medical devices. Regulator famhp.be (opens an external site) — accessed 22 October 2026
Federal Agency for Medicines and Health Products (FAMHP / FAGG / AFMPS) (2026). Compassionate use – Medical need. Regulator famhp.be (opens an external site) — accessed 22 October 2026
GOV.UK (2026). Request clinical waste collection. Regulator gov.uk (opens an external site) — accessed 20 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2023). Toezicht op online medicijnen. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2023). Waarschuwing voor vervalste injectiepennen van diabetesmedicijn Ozempic. Regulator igj.nl (opens an external site) — accessed 20 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2025). Inspectie maakt zich zorgen over toename van online-nepapotheken. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2025). Operatie SHIELD: IGJ en Douane nemen 60.000 pillen in beslag. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2025). Illegale handel in geneesmiddelen. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2025). Eigen bereidingen apotheek. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Online medicijnen. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Leveren op artsenverklaring. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Vragen over afleveren geneesmiddelen zonder handelsvergunning. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Standpunt IGJ over off-label voorschrijven (geactualiseerd februari 2026, aangepast mei 2026). Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). IGJ waarschuwt Europese autoriteiten voor gestolen medicijnen. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Inspectie Gezondheidszorg en Jeugd (IGJ) en College ter Beoordeling van Geneesmiddelen (CBG) (2025). IGJ en CBG waarschuwen voor illegaal online aanbod van medicijnen. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2023). MHRA warns of unsafe fake weight loss pens. GOV.UK. Regulator gov.uk (opens an external site) — accessed 20 October 2026
Medicines and Healthcare products Regulatory Agency (2025). Supply unlicensed medicinal products (specials). GOV.UK. Regulator gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2025). MHRA smashes major illicit weight loss medicine production facility in record seizure. GOV.UK. Regulator gov.uk (opens an external site) — accessed 20 October 2026
Medicines and Healthcare products Regulatory Agency (2026). Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. GOV.UK. Regulator gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2026). No summer shortcut for safe weight loss. GOV.UK. Regulator gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2026). Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines. GOV.UK. Regulator gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2026). MHRA seizes illegal medicines worth almost £45m in 2025 – disrupting major criminal networks. GOV.UK. Regulator gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2026). MHRA Products: search results for 'bremelanotide' and 'vyleesi'. Regulator products.mhra.gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2026). GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK. Regulator gov.uk (opens an external site) — accessed 20 October 2026
Medicines and Healthcare products Regulatory Agency (2026). MHRA Products: search results for 'tesamorelin' and 'egrifta'. Regulator products.mhra.gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2026). Falsified Mounjaro KwikPen 15mg pre-filled pens (Drug Safety Update). GOV.UK. Regulator gov.uk (opens an external site) — accessed 20 October 2026
Medicines and Healthcare products Regulatory Agency (MHRA) (2021). FOI 21/1237: Number of reports received via the Yellow Card scheme for melanotan II products including nasal sprays and injections between 2011-2021. Regulator assets.publishing.service.gov.uk (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (MHRA) (2024). FOI 24/274: Side effects reports of melanotan II products. Regulator assets.publishing.service.gov.uk (opens an external site) — accessed 22 October 2026
Parks MH (U.S. Food and Drug Administration, Center for Drug Evaluation and Research) (2010). Division Director Summary Review, NDA 22-505 (Egrifta, tesamorelin acetate). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Landelijk Centrum Hygiëne en Veiligheid (2026). Hygiënerichtlijn voor piercen. Regulator rivm.nl (opens an external site) — accessed 20 October 2026
Rijksoverheid (Dutch central government) (2026). Hoe hoog zijn de boetes in Nederland?. Regulator rijksoverheid.nl (opens an external site) — accessed 22 October 2026
Rijksoverheid (Government of the Netherlands) (2026). Wat moet ik doen als iemand dringend medische hulp nodig heeft?. Regulator rijksoverheid.nl (opens an external site) — accessed 20 October 2026
Rijksoverheid (Government of the Netherlands) (2026). Wanneer moet ik naar de huisartsenpost of de spoedeisende hulppost?. Regulator rijksoverheid.nl (opens an external site) — accessed 20 October 2026
Rijksoverheid (Government of the Netherlands) (2026). Waar kan ik klein chemisch afval (kca) inleveren?. Regulator rijksoverheid.nl (opens an external site) — accessed 20 October 2026
Rijksoverheid (Ministerie van Volksgezondheid, Welzijn en Sport) (2025). Hoe controleer ik of een online aanbieder van medicijnen betrouwbaar is?. Regulator rijksoverheid.nl (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (1993). Lyophilization of Parenteral (7/93): Guide to Inspections. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2010). NDA approval letter, NDA 022505 (Egrifta, tesamorelin for injection). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2016). Debarment Order (FR Doc. 2016-27244), 14 November 2016. Federal Register. Regulator federalregister.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2016). GRAS Notice Inventory: GRN No. 635, nicotinamide riboside chloride (ChromaDex, Inc.). Regulator hfpappexternal.fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2018). Frances Oldham Kelsey: Medical reviewer famous for averting a public health tragedy. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2019). NDA 210557 approval letter to AMAG Pharmaceuticals (Vyleesi, bremelanotide), 21 June 2019. Drugs@FDA. Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2019). Supplement approval letter, NDA 022505/S-012 and S-013 (Egrifta and Egrifta SV). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2020). FDA works to ensure smooth regulatory transition of insulin and other biological products. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2020). BeSafeRx: Considering an Online Pharmacy?. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2020). Notice to Compounders: Changes that affect compounding as of March 23, 2020. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2021). DOs and DON'Ts of Proper Sharps Disposal. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2021). Sharps Disposal Containers. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2021). What to Do if You Can't Find a Sharps Disposal Container. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2023). Milestones in U.S. Food and Drug Law. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2023). Best Way to Get Rid of Used Needles and Other Sharps. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2024). FDA Briefing Document for CJC-1295-Related Bulk Drug Substances (CJC-1295 (free base), CJC-1295 acetate, CJC-1295 with drug affinity complex (DAC) (free base), CJC-1295 DAC acetate and CJC-1295 DAC trifluoroacetate), Pharmacy Compounding Advisory Committee meeting, 4 December 2024. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2024). October 29, 2024: Meeting of the Pharmacy Compounding Advisory Committee. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2024). FDA Evaluation of Ipamorelin-related Bulk Drug Substances (Ipamorelin (free base) and Ipamorelin acetate) for Inclusion on the 503A Bulk Drug Substances List (briefing document 4, Pharmacy Compounding Advisory Committee, 29 October 2024). Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2024). FDA PM Presentations, Pharmacy Compounding Advisory Committee meeting, 29 October 2024. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2024). Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2024). FDA Briefing Document for Thymosin Alpha-1 Related Bulk Drug Substances (Thymosin alpha-1 (free base) and Thymosin alpha-1 acetate), Pharmacy Compounding Advisory Committee meeting, 4 December 2024. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2024). FDA Briefing Document: Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate) for Inclusion on the 503A Bulk Drug Substances List, Pharmacy Compounding Advisory Committee, 4 December 2024. Regulator fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2025). Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2025). December 4, 2024: Meeting of the Pharmacy Compounding Advisory Committee (updated meeting time and public participation information). Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2025). Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories 1–3), updated 21 March 2025. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2025). Personal Importation. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2025). FDA Grants Accelerated Approval to First Treatment for Barth Syndrome (press release, 19 September 2025). Regulator fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2025). NDA 215244 Accelerated Approval letter: Forzinity (elamipretide) injection, Stealth BioTherapeutics Inc.. Regulator accessdata.fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2025). Final Summary Minutes of the Cardiovascular and Renal Drugs Advisory Committee Meeting, 10 October 2024 (NDA 215244, elamipretide, Barth syndrome). Regulator fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2025). Supplement approval letter, BLA 022505/S-020 (Egrifta WR). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 050574 (Sandimmune cyclosporine oral solution). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). FDA Approves First New Molecular Entity Under National Priority Voucher Program. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). FDA Briefing Document Introduction, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Questions, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). FDA Presentations, Pharmacy Compounding Advisory Committee meeting, 23 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1–3), updated 14 May 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: BLA 018780 (Humulin R, insulin human). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 019010 (Lupron, leuprolide acetate injection). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 019667 (Sandostatin, octreotide acetate injection). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 021773 (Byetta, exenatide injection). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 022341 (Victoza, liraglutide injection). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: BLA 022505 (Egrifta, tesamorelin). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 210557 (Vyleesi, bremelanotide acetate injection). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 210797 (Scenesse, afamelanotide implant). Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). FDA Briefing Document for KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate), Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (FR Doc. 2026-08552). Federal Register. Regulator federalregister.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Meeting of the Pharmacy Compounding Advisory Committee (early announcement: meeting before the end of February 2027). Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). FDA Briefing Document for Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Warning Letters (searchable database). Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 209637 (Ozempic, semaglutide injection). Regulator accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 213051 (Rybelsus and Ozempic semaglutide tablets). Regulator accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 215256 (Wegovy, semaglutide injection). Regulator accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 218316 (Wegovy, semaglutide tablets). Regulator accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period (FR Doc. 2026-12937). Federal Register. Regulator federalregister.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). 2026 Meeting Materials, Pharmacy Compounding Advisory Committee. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List (FR Doc. 2026-07361). Federal Register. Regulator federalregister.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Bulk Drug Substances Used in Compounding. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). FDA Briefing Document for MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). 510(k) Premarket Notification database: K953853, Iamin Gel Wound Dressing (ProCyte Corp.). Regulator accessdata.fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 215244, Forzinity (elamipretide hydrochloride) injection. Regulator accessdata.fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2026). FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 215866 (Mounjaro, tirzepatide injection). Regulator accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 217806 (Zepbound, tirzepatide injection). Regulator accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (FDA History Office) (2022). 100 Years of Insulin. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2005). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2019). NDA 210557 Multi-Discipline Review (Vyleesi, bremelanotide). Drugs@FDA. Regulator accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration, Human Foods Program (2025). Response to citizen petition FDA-2023-P-0872 (Natural Products Association and Alliance for Natural Health USA) on the regulatory status of beta-nicotinamide mononucleotide (NMN): petition granted in part and denied in part. Regulations.gov, document FDA-2023-P-0872-2754. Regulator regulations.gov (opens an external site) — accessed 23 October 2026
World Anti-Doping Agency (2014). The 2015 Prohibited List, International Standard (in effect 1 January 2015). Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2014). 2015 Prohibited List: Summary of Major Modifications and Explanatory Notes. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2017). Summary of Major Modifications and Explanatory Notes, 2018 Prohibited List. Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Anti-Doping Agency (2021). Summary of Major Modifications and Explanatory Notes, 2022 Prohibited List. Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Anti-Doping Agency (2021). World Anti-Doping Code 2021. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2022). International Standard for Therapeutic Use Exemptions (ISTUE) 2023. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2024). World Anti-Doping Code International Standard: Prohibited List 2025. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2024). Summary of Major Modifications and Explanatory Notes, 2025 Prohibited List. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2024). The 2025 Monitoring Program. Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Anti-Doping Agency (2025). World Anti-Doping Code International Standard: Prohibited List 2026. Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Anti-Doping Agency (2025). International Standard for Therapeutic Use Exemptions (ISTUE) 2027. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2025). The 2026 Monitoring Program. Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Anti-Doping Agency (2026). World Anti-Doping Code International Standard: Prohibited List 2027 (in effect 1 January 2027). Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Anti-Doping Agency (2026). World Anti-Doping Code 2027 (version 1.0). Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2026). 2027 Code and International Standards. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2026). Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. Regulator wada-ama.org (opens an external site) — accessed 22 October 2026
World Anti-Doping Agency (2026). Prohibited List. Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Anti-Doping Agency (2026). The 2027 Monitoring Program. Regulator wada-ama.org (opens an external site) — accessed 20 October 2026
World Health Organization (2024). WHO issues warning on falsified medicines used for diabetes treatment and weight loss. Regulator who.int (opens an external site) — accessed 20 October 2026
Zorginstituut Nederland (2024). Zorginstituut: geen vergoeding Wegovy voor obesitas wegens onduidelijkheid gezondheidseffecten. Regulator zorginstituutnederland.nl (opens an external site) — accessed 20 October 2026
Zorginstituut Nederland (2025). Zorginstituut: obesitasmedicijnen eerst beschikbaar voor mensen met hoogste ziektelast. Regulator zorginstituutnederland.nl (opens an external site) — accessed 20 October 2026
Zorginstituut Nederland (2026). Huisarts (Zvw). Regulator zorginstituutnederland.nl (opens an external site) — accessed 22 October 2026
Zorginstituut Nederland (2026). Semaglutide — Farmacotherapeutisch Kompas (preparaattekst). Farmacotherapeutisch Kompas. Regulator farmacotherapeutischkompas.nl (opens an external site) — accessed 20 October 2026
Zorginstituut Nederland (2026). Advies — wel of niet vergoeden semaglutide (Wegovy®) voor de behandeling van obesitas (werkagenda). Regulator zorginstituutnederland.nl (opens an external site) — accessed 20 October 2026
Zorginstituut Nederland (2026). Tirzepatide — Farmacotherapeutisch Kompas (preparaattekst). Farmacotherapeutisch Kompas. Regulator farmacotherapeutischkompas.nl (opens an external site) — accessed 20 October 2026
Zorginstituut Nederland (2026). Advies — wel of niet vergoeden tirzepatide (Mounjaro®) voor de behandeling van obesitas (werkagenda). Regulator zorginstituutnederland.nl (opens an external site) — accessed 20 October 2026

Official product information (28)

European Medicines Agency (2026). Trulicity (dulaglutide): EPAR — product information. Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Victoza (liraglutide): EPAR — product information. Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Byetta (exenatide): EPAR — product information (authorisation withdrawn). Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Scenesse (afamelanotide): EPAR — overview and product information. Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Imcivree (setmelanotide): EPAR — medicine overview. Official product information ema.europa.eu (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Ozempic (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Wegovy (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Rybelsus (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Mounjaro (tirzepatide): EPAR — overview and product information. Official product information ema.europa.eu (opens an external site) — accessed 20 October 2026
Hospira, Inc. / DailyMed (National Library of Medicine) (2026). Bacteriostatic Water for Injection, USP: prescribing information. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 20 October 2026
Hospira, Inc. / DailyMed (National Library of Medicine) (2026). Sterile Water for Injection, USP: prescribing information. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2011). REGRANEX (becaplermin) Gel 0.01% — Prescribing Information (2011), including boxed warning on increased rate of mortality secondary to malignancy. Drugs@FDA. Official product information accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2018). REGRANEX (becaplermin) Gel — Prescribing Information (2018): boxed warning on cancer mortality removed 11/2018; malignancy warning retained. Drugs@FDA. Official product information accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration (2020). VYLEESI (bremelanotide injection), for subcutaneous use: prescribing information, revised 10/2020 (NDA 210557, supplement 2). Drugs@FDA. Official product information accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2024). EGRIFTA SV (tesamorelin) for injection: prescribing information (revised February 2024), BLA 022505/S-018. Official product information accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2025). EGRIFTA WR (tesamorelin) for injection: prescribing information (revised March 2025), BLA 022505/S-020. Official product information accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (Drugs@FDA) (2019). Desmopressin Acetate Tablets — prescribing information (revised 10/2019). Official product information accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2025). VYLEESI (bremelanotide injection): prescribing information. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2026). EGRIFTA SV (tesamorelin for injection): prescribing information and instructions for use. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2026). EGRIFTA WR (tesamorelin) for injection: prescribing information, patient information and instructions for use. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration / Eli Lilly and Company (2026). FOUNDAYO (orforglipron) tablets, for oral use — prescribing information (revised 07/2026). Official product information accessdata.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration / Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection — prescribing information (revised 08/2026). Official product information accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration / Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection — prescribing information (revised 08/2026). Official product information accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration / Novo Nordisk (2026). OZEMPIC (semaglutide) injection — prescribing information (revised 05/2026). Official product information accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration / Novo Nordisk (2026). WEGOVY (semaglutide) injection and tablets — prescribing information (revised 06/2026). Official product information accessdata.fda.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration; Stealth BioTherapeutics Inc. (2025). FORZINITY (elamipretide) injection, for subcutaneous use: Prescribing Information (revised 9/2025). Official product information accessdata.fda.gov (opens an external site) — accessed 23 October 2026
U.S. National Library of Medicine (DailyMed) (2025). BYETTA (exenatide) injection: prescribing information. DailyMed. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 22 October 2026
U.S. National Library of Medicine (DailyMed) (2026). LUPRON DEPOT (leuprolide acetate for depot suspension): prescribing information. DailyMed. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 22 October 2026

Guideline (3)

American Diabetes Association Professional Practice Committee for Diabetes (2026). 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care 49:S132-S149. Guideline doi:10.2337/dc26-S006 (opens an external site)
Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, et al. (2016). New Insulin Delivery Recommendations. Mayo Clinic Proceedings 91:1231-1255. Guideline doi:10.1016/j.mayocp.2016.06.010 (opens an external site)
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews 35:341-375. Guideline doi:10.1210/er.2013-1058 (opens an external site)

Clinical trial (98)

Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics 53:183-189. Clinical trial doi:10.1016/j.archger.2010.10.004 (opens an external site)
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. (2019). PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 42:1724-1732. Clinical trial doi:10.2337/dc19-0749 (opens an external site)
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine 393:26-36. Clinical trial doi:10.1056/NEJMoa2416394 (opens an external site)
Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331:38-48. Clinical trial doi:10.1001/jama.2023.24945 (opens an external site)
Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, et al. (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet 407:2402-2413. Clinical trial doi:10.1016/S0140-6736(26)00967-0 (opens an external site)
Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology 69:1420-1429. Clinical trial doi:10.1001/archneurol.2012.1970 (opens an external site)
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease 29:1527-1534. Clinical trial doi:10.1007/s00384-014-2030-8 (opens an external site)
Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet 408:1455-1472. Clinical trial doi:10.1016/S0140-6736(26)01861-1 (opens an external site)
Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism 34:396-407.e6. Clinical trial doi:10.1016/j.cmet.2022.02.001 (opens an external site)
Brakedal B, Skeie GO, Derad C, Alstadhaug KB, Anundskås I, Berven H, et al. (2026). Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA. Clinical trial doi:10.1001/jama.2026.18828 (opens an external site)
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. (2001). Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. The Journal of Clinical Endocrinology and Metabolism 86:5083-5086. Clinical trial doi:10.1210/jcem.86.10.8098 (opens an external site)
Butler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S, et al. (2020). Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure 26:429-437. Clinical trial doi:10.1016/j.cardfail.2020.02.001 (opens an external site)
Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS (1998). Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 27:1383-1387. Clinical trial doi:10.1002/hep.510270527 (opens an external site)
Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health (London, England) 12:325-337. Clinical trial doi:10.2217/whe-2016-0018 (opens an external site)
Clayton AH, Lucas J, DeRogatis LR, Jordan R (2017). Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clinical Therapeutics 39:514-526.e14. Clinical trial doi:10.1016/j.clinthera.2017.01.018 (opens an external site)
Clemmons DR, Miller S, Mamputu JC (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One 12:e0179538. Clinical trial doi:10.1371/journal.pone.0179538 (opens an external site)
Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology 13:674-684. Clinical trial doi:10.1016/S2213-8587(25)00092-0 (opens an external site)
Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet 407:2167-2179. Clinical trial doi:10.1016/S0140-6736(26)00459-9 (opens an external site)
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet 398:1811-1824. Clinical trial doi:10.1016/S0140-6736(21)02188-7 (opens an external site)
Diamond LE, Earle DC, Garcia WD, Spana C (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 65:755-759. Clinical trial doi:10.1016/j.urology.2004.10.060 (opens an external site)
Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The Journal of Sexual Medicine 3:628-638. Clinical trial doi:10.1111/j.1743-6109.2006.00268.x (opens an external site)
Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research 16:51-59. Clinical trial doi:10.1038/sj.ijir.3901139 (opens an external site)
Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. The American Journal of Clinical Nutrition 108:343-353. Clinical trial doi:10.1093/ajcn/nqy132 (opens an external site)
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences 58:1777-1784. Clinical trial doi:10.1016/0024-3205(96)00160-9 (opens an external site)
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine 324:781-788. Clinical trial doi:10.1056/NEJM199103213241201 (opens an external site)
Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F, et al. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. The Journal of Infectious Diseases 231:1230-1238. Clinical trial doi:10.1093/infdis/jiaf012 (opens an external site)
Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine 357:2359-2370. Clinical trial doi:10.1056/NEJMoa072375 (opens an external site)
Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22:1719-1728. Clinical trial doi:10.1097/QAD.0b013e32830a5058 (opens an external site)
Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes 53:311-322. Clinical trial doi:10.1097/QAI.0b013e3181cbdaff (opens an external site)
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine 385:503-515. Clinical trial doi:10.1056/NEJMoa2107519 (opens an external site)
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet 392:2180-2193. Clinical trial doi:10.1016/S0140-6736(18)32260-8 (opens an external site)
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism 23:754-762. Clinical trial doi:10.1111/dom.14280 (opens an external site)
Gibson CM, Giugliano RP, Kloner RA, Bode C, Tendera M, Jánosi A, et al. (2016). EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal 37:1296-1303. Clinical trial doi:10.1093/eurheartj/ehv597 (opens an external site)
Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research 16:1412-1416. Clinical trial doi:10.1023/a:1018955126402 (opens an external site)
Guarnera G, DeRosa A, Camerini R; 8 European sites (2010). The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences 1194:207-212. Clinical trial doi:10.1111/j.1749-6632.2010.05490.x (opens an external site)
Hannon TS, Chao LC, Barrientos-Pérez M, Pamidipati KC, Landó LF, Lee CJ, et al. (2025). Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 406:1484-1496. Clinical trial doi:10.1016/S0140-6736(25)01774-X (opens an external site)
Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. (2023). Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 46:998-1004. Clinical trial doi:10.2337/dc22-1710 (opens an external site)
Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. (2022). Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The Lancet Diabetes & Endocrinology 10:418-429. Clinical trial doi:10.1016/S2213-8587(22)00085-7 (opens an external site)
Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, et al. (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet 407:2305-2318. Clinical trial doi:10.1016/S0140-6736(26)00656-2 (opens an external site)
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 381:841-851. Clinical trial doi:10.1056/NEJMoa1901118 (opens an external site)
Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology and Metabolism 91:4792-4797. Clinical trial doi:10.1210/jc.2006-1702 (opens an external site)
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 387:205-216. Clinical trial doi:10.1056/NEJMoa2206038 (opens an external site)
Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Clinical trial doi:10.1056/NEJMoa2604169 (opens an external site)
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine 389:514-526. Clinical trial doi:10.1056/NEJMoa2301972 (opens an external site)
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. (2025). Tirzepatide for obesity treatment and diabetes prevention. New England Journal of Medicine 392:958-971. Clinical trial doi:10.1056/NEJMoa2410819 (opens an external site)
Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, et al. (2025). Once-monthly maridebart cafraglutide for the treatment of obesity — a phase 2 trial. New England Journal of Medicine 393:843-857. Clinical trial doi:10.1056/NEJMoa2504214 (opens an external site)
Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J, et al. (2025). Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, Obesity and Metabolism 27:6988-6998. Clinical trial doi:10.1111/dom.70097 (opens an external site)
Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A (2017). Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia 60:1390-1399. Clinical trial doi:10.1007/s00125-017-4289-0 (opens an external site)
Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology 101:e238-e252. Clinical trial doi:10.1212/WNL.0000000000207402 (opens an external site)
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology 134:899-908. Clinical trial doi:10.1097/AOG.0000000000003500 (opens an external site)
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine 389:2221-2232. Clinical trial doi:10.1056/NEJMoa2307563 (opens an external site)
Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. (2023). Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The Lancet Gastroenterology & Hepatology 8:511-522. Clinical trial doi:10.1016/S2468-1253(23)00068-7 (opens an external site)
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. New England Journal of Medicine 391:299-310. Clinical trial doi:10.1056/NEJMoa2401943 (opens an external site)
Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK (2012). Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism 97:4769-4779. Clinical trial doi:10.1210/jc.2012-2794 (opens an external site)
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine 391:1193-1205. Clinical trial doi:10.1056/NEJMoa2404881 (opens an external site)
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 375:1834-1844. Clinical trial doi:10.1056/NEJMoa1607141 (opens an external site)
Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nature Communications 9:1286. Clinical trial doi:10.1038/s41467-018-03421-7 (opens an external site)
McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. (2025). Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. New England Journal of Medicine 392:2001-2012. Clinical trial doi:10.1056/NEJMoa2501006 (opens an external site)
Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman RR, Silva M, Roach KC, Simmons F, Milstein S, Gordon SC, Ehrinpreis MN (1999). Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Journal of Viral Hepatitis 6:397-403. Clinical trial doi:10.1046/j.1365-2893.1999.00181.x (opens an external site)
Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine 149:601-611. Clinical trial doi:10.7326/0003-4819-149-9-200811040-00003 (opens an external site)
Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. (2025). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. New England Journal of Medicine 393:2409-2420. Clinical trial doi:10.1056/NEJMoa2505928 (opens an external site)
Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. (2025). Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine 392:427-437. Clinical trial doi:10.1056/NEJMoa2410027 (opens an external site)
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine 391:109-121. Clinical trial doi:10.1056/NEJMoa2403347 (opens an external site)
Reid Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine 23:471-478. Clinical trial doi:10.1038/s41436-020-01006-8 (opens an external site)
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research 16:135-142. Clinical trial doi:10.1038/sj.ijir.3901200 (opens an external site)
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 402:529-544. Clinical trial doi:10.1016/S0140-6736(23)01053-X (opens an external site)
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet 398:143-155. Clinical trial doi:10.1016/S0140-6736(21)01324-6 (opens an external site)
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333. Clinical trial doi:10.1001/jama.288.3.321 (opens an external site)
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325:1414-1425. Clinical trial doi:10.1001/jama.2021.3224 (opens an external site)
Ruff D, Crockford D, Girardi G, Zhang Y (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences 1194:223-229. Clinical trial doi:10.1111/j.1749-6632.2010.05474.x (opens an external site)
Safarinejad MR, Hosseini SY (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of Urology 179:1066-1071. Clinical trial doi:10.1016/j.juro.2007.10.063 (opens an external site)
Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine 30:2037-2048. Clinical trial doi:10.1038/s41591-024-03018-2 (opens an external site)
Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. (2025). Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. New England Journal of Medicine 392:2089-2099. Clinical trial doi:10.1056/NEJMoa2413258 (opens an external site)
Schroter S, Black N, Evans S, Godlee F, Osorio L, Smith R (2008). What errors do peer reviewers detect, and does training improve their ability to detect them?. Journal of the Royal Society of Medicine 101:507-514. Clinical trial doi:10.1258/jrsm.2008.080062 (opens an external site)
Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology 134:909-917. Clinical trial doi:10.1097/AOG.0000000000003514 (opens an external site)
Sosne G, Dunn SP, Kim C (2015). Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea 34:491-496. Clinical trial doi:10.1097/ICO.0000000000000379 (opens an external site)
Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, et al. (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences 24:554. Clinical trial doi:10.3390/ijms24010554 (opens an external site)
Sosne G, Ousler GW (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clinical Ophthalmology 9:877-884. Clinical trial doi:10.2147/OPTH.S80954 (opens an external site)
Spana C, Jordan R, Fischkoff S (2022). Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, Obesity & Metabolism 24:1084-1093. Clinical trial doi:10.1111/dom.14672 (opens an external site)
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 312:380-389. Clinical trial doi:10.1001/jama.2014.8334 (opens an external site)
Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV 6:e821-e830. Clinical trial doi:10.1016/S2352-3018(19)30338-8 (opens an external site)
Stewart CE, French KP, Wright TJ, Wilhoit K, Randolph KM, Danesi CP, et al. (2026). The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci 44:100616. Clinical trial doi:10.1016/j.ensci.2026.100616 (opens an external site)
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism 91:799-805. Clinical trial doi:10.1210/jc.2005-1536 (opens an external site)
Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine 26:101138. Clinical trial doi:10.1016/j.gim.2024.101138 (opens an external site)
Thurston L, Hunjan T, Mills EG, Wall MB, Ertl N, Phylactou M, Muzi B, Patel B, Alexander EC, Suladze S, Modi M, Eng PC, Bassett PA, Abbara A, Goldmeier D, Comninos AN, Dhillo WS (2022). Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. The Journal of Clinical Investigation 132. Clinical trial doi:10.1172/JCI152341 (opens an external site)
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet 400:1869-1881. Clinical trial doi:10.1016/S0140-6736(22)02033-5 (opens an external site)
Wang X, Liu L, Qi L, Lei C, Li P, et al. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine 25:8222-8228. Clinical trial doi:10.1111/jcmm.16693 (opens an external site)
Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology 160:389-393. Clinical trial PMID 9679884 (opens an external site)
Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 56:641-646. Clinical trial doi:10.1016/s0090-4295(00)00680-4 (opens an external site)
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England Journal of Medicine 389:877-888. Clinical trial doi:10.1056/NEJMoa2302392 (opens an external site)
Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine 393:1077-1087. Clinical trial doi:10.1056/NEJMoa2500969 (opens an external site)
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 384:989-1002. Clinical trial doi:10.1056/NEJMoa2032183 (opens an external site)
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism 24:1553-1564. Clinical trial doi:10.1111/dom.14725 (opens an external site)
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. (2001). Ghrelin enhances appetite and increases food intake in humans. The Journal of Clinical Endocrinology and Metabolism 86:5992. Clinical trial doi:10.1210/jcem.86.12.8111 (opens an external site)
Wu J, Pei F, Zhou L, Li W, Sun R, Li Y, Wang Z, He Z, Zhang X, Jin X, et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ 388:e082583. Clinical trial doi:10.1136/bmj-2024-082583 (opens an external site)
Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 372:1224-1229. Clinical trial doi:10.1126/science.abe9985 (opens an external site)
Yu X, Xu J, Cao J, Xu Q, Chen H, Yu D, Yao X, Chen K, Ma L (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. American Journal of Cardiovascular Drugs 26:97-106. Clinical trial doi:10.1007/s40256-025-00764-7 (opens an external site)
Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, et al. (2025). Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovascular Research 121:2747-2758. Clinical trial doi:10.1093/cvr/cvaf223 (opens an external site)

Meta-analysis (13)

Badran AS, Helal A, Shata KS, Ayesh H (2026). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice 20:2-12. Meta-analysis doi:10.1016/j.orcp.2026.01.002 (opens an external site)
Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303:1180-1187. Meta-analysis doi:10.1001/jama.2010.310 (opens an external site)
Boniol M, Autier P, Boyle P, Gandini S (2012). Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 345:e4757. Meta-analysis doi:10.1136/bmj.e4757 (opens an external site)
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, et al. (2026). Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Medicine 5:e003026. Meta-analysis doi:10.1136/bmjmed-2026-003026 (opens an external site)
Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology and Metabolism 95:4291-4304. Meta-analysis doi:10.1210/jc.2010-0490 (opens an external site)
Gu B, Zhou Y, Nie Y, Wang L, Liang L, Liao Z, Wen J, Guan X, Chen M, Wu J, Pei F (2025). Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology 15:1673959. Meta-analysis doi:10.3389/fcimb.2025.1673959 (opens an external site)
He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. (2022). Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine 182:513-519. Meta-analysis doi:10.1001/jamainternmed.2022.0338 (opens an external site)
Kruoch Z, Choo AY, Kemp A, Gonzales M, Yim TW, et al. (2025). Medical and surgical interventions for neurotrophic keratopathy. Cochrane Database of Systematic Reviews 12:CD015723. Meta-analysis doi:10.1002/14651858.CD015723.pub2 (opens an external site)
Pasqualotto E, Ferreira ROM, Chavez MP, Hohl A, Ronsoni MF, Pasqualotto T, et al. (2024). Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open 24:100321. Meta-analysis doi:10.1016/j.metop.2024.100321 (opens an external site)
Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. The Lancet 363:1346-1353. Meta-analysis doi:10.1016/S0140-6736(04)16044-3 (opens an external site)
Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995). Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412. Meta-analysis doi:10.1001/jama.273.5.408 (opens an external site)
Spielmans GI (2021). Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of Sex Research 58:1085-1105. Meta-analysis doi:10.1080/00224499.2021.1885601 (opens an external site)
Stampfer MJ, Colditz GA (1991). Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 20:47-63. Meta-analysis doi:10.1016/0091-7435(91)90006-p (opens an external site)

Review (86)

Andersson F (1992). The drug lag issue: the debate seen from an international perspective. International Journal of Health Services 22:53-72. Review doi:10.2190/9Y32-X86Y-M3F0-JQFC (opens an external site)
Berg KA, Clarke WP (2018). Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. International Journal of Neuropsychopharmacology 21:962-977. Review doi:10.1093/ijnp/pyy071 (opens an external site)
Böhm M, Luger T (2019). Are melanocortin peptides future therapeutics for cutaneous wound healing?. Experimental Dermatology 28:219-224. Review doi:10.1111/exd.13887 (opens an external site)
Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny RJ (2020). Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Advanced Drug Delivery Reviews 157:2-36. Review doi:10.1016/j.addr.2020.05.007 (opens an external site)
Brunt TM, Niesink RJ (2011). The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison. Drug Testing and Analysis 3:621-634. Review doi:10.1002/dta.323 (opens an external site)
Brzoska T, Luger TA, Maaser C, Abels C, Böhm M (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews 29:581-602. Review doi:10.1210/er.2007-0027 (opens an external site)
Burian EA, Jemec GBE (2019). Eruptive Melanocytic Nevi: A Review. American Journal of Clinical Dermatology 20:669-682. Review doi:10.1007/s40257-019-00444-8 (opens an external site)
Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR (2013). Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 14:365-376. Review doi:10.1038/nrn3475 (opens an external site)
Carmeliet P, Jain RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307. Review doi:10.1038/nature10144 (opens an external site)
Coutinho LFD, De Oliveira Neves LF, Camilo RP (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. Journal of Sports Medicine and Physical Fitness 66:880-885. Review doi:10.23736/S0022-4707.26.17773-1 (opens an external site)
D'Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B (2014). Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 101:2-30. Review doi:10.1016/j.jpba.2014.06.012 (opens an external site)
Davenport AP, Scully CCG, de Graaf C, Brown AJH, Maguire JJ (2020). Advances in therapeutic peptides targeting G protein-coupled receptors. Nature Reviews Drug Discovery 19:389-413. Review doi:10.1038/s41573-020-0062-z (opens an external site)
de Sousa LMM, Vicente VAN, Donato J (2025). Negative Feedback Loops and Hormonal Factors that Regulate GH Secretion. Endocrinology 166:bqaf139. Review doi:10.1210/endocr/bqaf139 (opens an external site)
Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM (2022). Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics 14:716. Review doi:10.3390/pharmaceutics14040716 (opens an external site)
Dhillon S, Keam SJ (2019). Bremelanotide: First Approval. Drugs 79:1599-1606. Review doi:10.1007/s40265-019-01187-w (opens an external site)
Di L (2015). Strategic approaches to optimizing peptide ADME properties. The AAPS Journal 17:134-143. Review doi:10.1208/s12248-014-9687-3 (opens an external site)
Diao L, Meibohm B (2013). Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clinical Pharmacokinetics 52:855-868. Review doi:10.1007/s40262-013-0079-0 (opens an external site)
Drucker DJ (2020). Advances in oral peptide therapeutics. Nature Reviews Drug Discovery 19:277-289. Review doi:10.1038/s41573-019-0053-0 (opens an external site)
Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN (2026). IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research 223:108077. Review doi:10.1016/j.phrs.2025.108077 (opens an external site)
Fleming TR, DeMets DL (1996). Surrogate end points in clinical trials: are we being misled?. Annals of Internal Medicine 125:605-613. Review doi:10.7326/0003-4819-125-7-199610010-00011 (opens an external site)
Fridkin M, Najjar VA (1989). Tuftsin: its chemistry, biology, and clinical potential. Critical Reviews in Biochemistry and Molecular Biology 24:1-40. Review doi:10.3109/10409238909082550 (opens an external site)
Fugate JE, Rabinstein AA (2015). Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. The Lancet Neurology 14:914-925. Review doi:10.1016/S1474-4422(15)00111-8 (opens an external site)
Garcia J, Costa VM, Carvalho A, Baptista P, de Pinho PG, de Lourdes Bastos M, Carvalho F (2015). Amanita phalloides poisoning: Mechanisms of toxicity and treatment. Food and Chemical Toxicology 86:41-55. Review doi:10.1016/j.fct.2015.09.008 (opens an external site)
Gell S, Dave S, Willis E, Vitale EJ, Woloshin S, Heiss R (2026). Prescription drug promotion by social media influencers: a systematic scoping review. JAMA Network Open 9:e262738. Review doi:10.1001/jamanetworkopen.2026.2738 (opens an external site)
Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S (2007). Helping doctors and patients make sense of health statistics. Psychological Science in the Public Interest 8:53-96. Review doi:10.1111/j.1539-6053.2008.00033.x (opens an external site)
Godic A, Townsend J (2026). Intravenous longevity therapy: a critical review of evidence, mechanisms, and clinical utility. Acta Dermatovenerologica Alpina, Pannonica et Adriatica 35:39-43. Review PMID 41915584 (opens an external site)
Goldstein AL, Hannappel E, Kleinman HK (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine 11:421-429. Review doi:10.1016/j.molmed.2005.07.004 (opens an external site)
Gravina AG, Pellegrino R, Durante T, Palladino G, Imperio G, D'Amico G, Trotta MC, Dallio M, Romeo M, D'Amico M, Federico A (2023). The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Cells 12:1889. Review doi:10.3390/cells12141889 (opens an external site)
Habbema L, Halk AB, Neumann M, Bergman W (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology 56:975-980. Review doi:10.1111/ijd.13585 (opens an external site)
Hadley ME (2005). Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 26:1687-1689. Review doi:10.1016/j.peptides.2005.01.023 (opens an external site)
Hadley ME, Dorr RT (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 27:921-930. Review doi:10.1016/j.peptides.2005.01.029 (opens an external site)
Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144:646-674. Review doi:10.1016/j.cell.2011.02.013 (opens an external site)
Haraldsson B, Nyström J, Deen WM (2008). Properties of the glomerular barrier and mechanisms of proteinuria. Physiological Reviews 88:451-487. Review doi:10.1152/physrev.00055.2006 (opens an external site)
Harris JM, Chess RB (2003). Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery 2:214-221. Review doi:10.1038/nrd1033 (opens an external site)
Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE (2017). Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery 16:829-842. Review doi:10.1038/nrd.2017.178 (opens an external site)
Hazell L, Shakir SA (2006). Under-reporting of adverse drug reactions: a systematic review. Drug Safety 29:385-396. Review doi:10.2165/00002018-200629050-00003 (opens an external site)
Holst JJ, Rosenkilde MM (2020). GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists. Journal of Clinical Endocrinology and Metabolism 105:e2710-e2716. Review doi:10.1210/clinem/dgaa327 (opens an external site)
Jebeile H, Danielsen YS, Sumithran P, Lorien S, Jardine IR, Baur LA, Lister NB (2025). GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk. Obesity Reviews 27:e70049. Review doi:10.1111/obr.70049 (opens an external site)
Józwiak M, Bauer M, Kamysz W, Kleczkowska P (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel) 18:185. Review doi:10.3390/ph18020185 (opens an external site)
Kaczynski MM, Zureikat RM, Kaczynski MR, Sitarz R, Karakuła-Juchnowicz H (2026). Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework. Biomedicines 14:1957. Review doi:10.3390/biomedicines14091957 (opens an external site)
Kim JH, Scialli AR (2011). Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicological Sciences 122:1-6. Review doi:10.1093/toxsci/kfr088 (opens an external site)
King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H (2007). Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry 7:1098-1106. Review PMID 17584130 (opens an external site)
Le Daré B, Ferron PJ, Gicquel T (2021). Toxic Effects of Amanitins: Repurposing Toxicities toward New Therapeutics. Toxins 13:417. Review doi:10.3390/toxins13060417 (opens an external site)
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 46:3-26. Review doi:10.1016/s0169-409x(00)00129-0 (opens an external site)
Luger TA, Brzoska T (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases 66 Suppl 3:iii52-iii55. Review doi:10.1136/ard.2007.079780 (opens an external site)
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2:MR000033. Review doi:10.1002/14651858.MR000033.pub3 (opens an external site)
Maghsoudi N, Tanguay J, Scarfone K, Rammohan I, Ziegler C, Werb D, Scheim AI (2022). Drug checking services for people who use drugs: a systematic review. Addiction 117:532-544. Review doi:10.1111/add.15734 (opens an external site)
Mannherz HG, Hannappel E (2009). The beta-thymosins: intracellular and extracellular activities of a versatile actin binding protein family. Cell Motility and the Cytoskeleton 66:839-851. Review doi:10.1002/cm.20371 (opens an external site)
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research 27:544-575. Review doi:10.1007/s11095-009-0045-6 (opens an external site)
Mao Y, Tokudome T, Kishimoto I (2014). The cardiovascular action of hexarelin. Journal of Geriatric Cardiology 11:253-258. Review doi:10.11909/j.issn.1671-5411.2014.03.007 (opens an external site)
Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR (2000). Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Progress in Hormone Research 55:237-266. Review PMID 11036940 (opens an external site)
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine 18:611-619. Review doi:10.1007/s12178-025-09990-7 (opens an external site)
Merriam GR, Schwartz RS, Vitiello MV (2003). Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine 22:41-48. Review doi:10.1385/ENDO:22:1:41 (opens an external site)
Mestas J, Hughes CCW (2004). Of mice and not men: differences between mouse and human immunology. Journal of Immunology 172:2731-2738. Review doi:10.4049/jimmunol.172.5.2731 (opens an external site)
Mintzes B, Tiefer L, Cosgrove L (2021). Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and Therapeutics Bulletin 59:185-188. Review doi:10.1136/dtb.2021.000020 (opens an external site)
Møller N, Jørgensen JO (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 30:152-177. Review doi:10.1210/er.2008-0027 (opens an external site)
Morgan CA, Herman N, White PA, Vesey G (2006). Preservation of micro-organisms by drying; a review. Journal of Microbiological Methods 66:183-193. Review doi:10.1016/j.mimet.2006.02.017 (opens an external site)
Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 30:72-130. Review doi:10.1016/j.molmet.2019.09.010 (opens an external site)
Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. (2015). Ghrelin. Molecular Metabolism 4:437-460. Review doi:10.1016/j.molmet.2015.03.005 (opens an external site)
Muttenthaler M, King GF, Adams DJ, Alewood PF (2021). Trends in peptide drug discovery. Nature Reviews Drug Discovery 20:309-325. Review doi:10.1038/s41573-020-00135-8 (opens an external site)
Neeland IJ, Linge J, Birkenfeld AL (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism 26 Suppl 4:16-27. Review doi:10.1111/dom.15728 (opens an external site)
Ogórek K, Nowak K, Wadych E, Ruzik L, Timerbaev AR, Matczuk M (2025). Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?. Molecules 30:136. Review doi:10.3390/molecules30010136 (opens an external site)
Paramonov VM, Mamaeva V, Sahlgren C, Rivero-Müller A (2015). Genetically-encoded tools for cAMP probing and modulation in living systems. Frontiers in Pharmacology 6:196. Review doi:10.3389/fphar.2015.00196 (opens an external site)
Poolton JT, Minett J, Kazmi A (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica 92. Review doi:10.52628/92.3.15837 (opens an external site)
Rajagopal S, Shenoy SK (2018). GPCR desensitization: Acute and prolonged phases. Cellular Signalling 41:9-16. Review doi:10.1016/j.cellsig.2017.01.024 (opens an external site)
Rosenberg AS (2006). Effects of protein aggregates: an immunologic perspective. The AAPS Journal 8:E501-E507. Review doi:10.1208/aapsj080359 (opens an external site)
Schaefer LM, Kerver GA, Allison KC, Kohoutek B, Steffen KJ (2025). Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance. The Psychiatric Clinics of North America 49:183-202. Review doi:10.1016/j.psc.2025.08.013 (opens an external site)
Schneier M, Razdan S, Miller AM, Briceno ME, Barua S (2020). Current technologies to endotoxin detection and removal for biopharmaceutical purification. Biotechnology and Bioengineering 117:2588-2609. Review doi:10.1002/bit.27362 (opens an external site)
Sengupta P (2013). The laboratory rat: relating its age with human's. International Journal of Preventive Medicine 4:624-630. Review PMID 23930179 (opens an external site)
Sharma V, McNeill JH (2009). To scale or not to scale: the principles of dose extrapolation. British Journal of Pharmacology 157:907-921. Review doi:10.1111/j.1476-5381.2009.00267.x (opens an external site)
Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, Turković B, Jagić V, Mildner B, Duvnjak M, et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology, Paris 87:313-327. Review doi:10.1016/0928-4257(93)90038-u (opens an external site)
Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra GP, Bartoli E, Derosa G (2015). Sulfonylureas and their use in clinical practice. Archives of Medical Science 11:840-848. Review doi:10.5114/aoms.2015.53304 (opens an external site)
Sosne G, Qiu P, Goldstein AL, Wheater M (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal 24:2144-2151. Review doi:10.1096/fj.09-142307 (opens an external site)
Sribenja S, Wongkham S, Wongkham C, Yao Q, Chen C (2013). Roles and mechanisms of β-thymosins in cell migration and cancer metastasis: an update. Cancer Investigation 31:103-110. Review doi:10.3109/07357907.2012.756111 (opens an external site)
Sulzmaier FJ, Jean C, Schlaepfer DD (2014). FAK in cancer: mechanistic findings and clinical applications. Nature Reviews Cancer 14:598-610. Review doi:10.1038/nrc3792 (opens an external site)
Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, et al. (2012). The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences 1270:37-44. Review doi:10.1111/j.1749-6632.2012.06717.x (opens an external site)
Vargesson N (2015). Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Research. Part C, Embryo Today: Reviews 105:140-156. Review doi:10.1002/bdrc.21096 (opens an external site)
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal 21:485-495. Review doi:10.1177/15563316251355551 (opens an external site)
Veldhuis JD, Anderson SM, Shah N, Bray M, Vick T, Gentili A, et al. (2001). Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Hormone & IGF Research 11 Suppl A:S25-S37. Review doi:10.1016/s1096-6374(01)80005-8 (opens an external site)
Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C (2022). Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy 7:48. Review doi:10.1038/s41392-022-00904-4 (opens an external site)
Werle M, Bernkop-Schnürch A (2006). Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367. Review doi:10.1007/s00726-005-0289-3 (opens an external site)
Wessells H, Levine N, Hadley ME, Dorr R, Hruby V (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research 12 Suppl 4:S74-S79. Review doi:10.1038/sj.ijir.3900582 (opens an external site)
Wettschureck N, Offermanns S (2005). Mammalian G proteins and their cell type specific functions. Physiological Reviews 85:1159-1204. Review doi:10.1152/physrev.00003.2005 (opens an external site)
Wolf Horrell EM, Boulanger MC, D'Orazio JA (2016). Melanocortin 1 Receptor: Structure, Function, and Regulation. Frontiers in Genetics 7:95. Review doi:10.3389/fgene.2016.00095 (opens an external site)
Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE (2017). Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus 7:20170030. Review doi:10.1098/rsfs.2017.0030 (opens an external site)
Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J (2021). Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharmaceutica Sinica B 11:2416-2448. Review doi:10.1016/j.apsb.2021.04.001 (opens an external site)

Research article (317)

Abdel-Malek Z, Swope VB, Suzuki I, Akcali C, Harriger MD, Boyce ST, Urabe K, Hearing VJ (1995). Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proceedings of the National Academy of Sciences of the United States of America 92:1789-1793. Research article doi:10.1073/pnas.92.5.1789 (opens an external site)
Adeghate E, Ponery AS (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinology Letters 25:403-406. Research article PMID 15665799 (opens an external site)
Al-Dulaimi S, Thomas R, Matta S, Roberts T (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 26:178. Research article doi:10.1007/s10522-025-10315-x (opens an external site)
Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ (1989). Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. Journal of Medicinal Chemistry 32:2555-2561. Research article doi:10.1021/jm00132a010 (opens an external site)
Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology. Endocrinology and Metabolism 291:E1290-E1294. Research article doi:10.1152/ajpendo.00201.2006 (opens an external site)
Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research 11:266-272. Research article doi:10.1054/ghir.2001.0239 (opens an external site)
Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 4:193-202. Research article doi:10.1023/a:1025114230714 (opens an external site)
Antonacci G, Bortignon E, Bolognesi M, Piano SS, Cadore A, Camuffo L, Venturini F, Faoro S, Favretto D, Romano A, Mengato D (2026). Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European Journal of Hospital Pharmacy 33:486-489. Research article doi:10.1136/ejhpharm-2025-004656 (opens an external site)
Aranda-Domene R, Orenes-Piñero E, Arribas-Leal JM, Canovas-Lopez S, Hernández-Cascales J (2023). Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart. Cardiovascular Diabetology 22:128. Research article doi:10.1186/s12933-023-01859-8 (opens an external site)
Ashraf AR, Mackey TK, Schmidt J, Kulcsár G, Vida RG, Li J, Fittler A (2024). Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases. JAMA Network Open 7:e2428280. Research article doi:10.1001/jamanetworkopen.2024.28280 (opens an external site)
Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, Domián BM, Li J, Csákó I, Fittler A (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research 26:e65440. Research article doi:10.2196/65440 (opens an external site)
Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, et al. (1996). Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. Journal of Clinical Investigation 97:839-844. Research article doi:10.1172/JCI118484 (opens an external site)
Banerjee I, Moore Morris T, Evans SM, Chen J (2013). Thymosin β4 is not required for embryonic viability or vascular development. Circulation Research 112:e25-e28. Research article doi:10.1161/CIRCRESAHA.111.300197 (opens an external site)
Banerjee I, Zhang J, Moore-Morris T, Lange S, Shen T, et al. (2012). Thymosin beta 4 is dispensable for murine cardiac development and function. Circulation Research 110:456-464. Research article doi:10.1161/CIRCRESAHA.111.258616 (opens an external site)
Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922). Pancreatic Extracts in the Treatment of Diabetes Mellitus. Canadian Medical Association Journal 12:141-146. Research article PMID 20314060 (opens an external site)
Barnetson RS, Ooi TK, Zhuang L, Halliday GM, Reid CM, Walker PC, Humphrey SM, Kleinig MJ (2006). [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. The Journal of Investigative Dermatology 126:1869-1878. Research article doi:10.1038/sj.jid.5700317 (opens an external site)
Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982). SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences 31:1133-1140. Research article doi:10.1016/0024-3205(82)90087-x (opens an external site)
Bebarta V, Luyten D, Heard K (2003). Emergency medicine animal research: does use of randomization and blinding affect the results?. Academic Emergency Medicine 10:684-687. Research article doi:10.1111/j.1553-2712.2003.tb00056.x (opens an external site)
Begley CG, Ellis LM (2012). Drug development: Raise standards for preclinical cancer research. Nature 483:531-533. Research article doi:10.1038/483531a (opens an external site)
Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E (1978). Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 202:631-633. Research article doi:10.1126/science.100883 (opens an external site)
Belcourt J, Ly P, White CM (2025). Bypassing prescribers and pharmacists: online purchasing of semaglutide and tirzepatide "for research purposes". Annals of Pharmacotherapy 59:485-490. Research article doi:10.1177/10600280241277551 (opens an external site)
Ben-Shlomo A, Deng N, Ding E, Yamamoto M, Mamelak A, Chesnokova V, Labadzhyan A, Melmed S (2020). DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. The Journal of Clinical Investigation 130:5738-5755. Research article doi:10.1172/JCI138540 (opens an external site)
Benoit SC, Sheldon RJ, Air EL, Messerschmidt P, Wilmer KA, Hodge KM, Jones MB, Eckstein DM, McOsker CC, Woods SC, Seeley RJ (2003). Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International Journal of Obesity and Related Metabolic Disorders 27:550-556. Research article doi:10.1038/sj.ijo.0802280 (opens an external site)
Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. (2023). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 46:384-390. Research article doi:10.2337/dc22-1148 (opens an external site)
Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery 37:822-837. Research article doi:10.52312/jdrs.2026.2951 (opens an external site)
Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology 24:1250-1261. Research article doi:10.1681/ASN.2012121216 (opens an external site)
Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC (1992). A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery 16:251-257. Research article doi:10.1067/mva.1992.37086 (opens an external site)
Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E (1999). Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. Journal of Endocrinological Investigation 22:266-272. Research article doi:10.1007/BF03343555 (opens an external site)
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. (2010). Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473-1486. Research article doi:10.1210/en.2009-1272 (opens an external site)
Blanco M, Hernández MT, Strauss KW, Amaya M (2013). Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism 39:445-453. Research article doi:10.1016/j.diabet.2013.05.006 (opens an external site)
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432:466-472. Research article doi:10.1038/nature03000 (opens an external site)
Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H (2002). CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research 90:844-849. Research article doi:10.1161/01.res.0000016164.02525.b4 (opens an external site)
Bonchev A (2026). Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel) 16:265. Research article doi:10.3390/life16020265 (opens an external site)
Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F (2006). Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Experimental Eye Research 83:1366-1372. Research article doi:10.1016/j.exer.2006.07.014 (opens an external site)
Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL (2025). Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology 267:110299. Research article doi:10.1016/j.neuropharm.2025.110299 (opens an external site)
Borner T, Geisler CE, Fortin SM, Cosgrove R, Alsina-Fernandez J, Dogra M, et al. (2021). GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes 70:2545-2553. Research article doi:10.2337/db21-0459 (opens an external site)
Boutron I, Dutton S, Ravaud P, Altman DG (2010). Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303:2058-2064. Research article doi:10.1001/jama.2010.651 (opens an external site)
Branine N (2026). Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus 18:e115260. Research article doi:10.7759/cureus.115260 (opens an external site)
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973). Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77-79. Research article doi:10.1126/science.179.4068.77 (opens an external site)
Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S (2009). Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology 60 Suppl 7:191-196. Research article PMID 20388964 (opens an external site)
Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A (2015). Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Testing and Analysis 7:164-172. Research article doi:10.1002/dta.1655 (opens an external site)
Briand F, Le Cudennec C, Grasset E, Breyner N, Bigot C, Dillard P, et al. (2026). Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring) 34 Suppl 1:43-53. Research article doi:10.1002/oby.70155 (opens an external site)
Brierley L, Nanni F, Polka JK, Dey G, Pálfy M, Fraser N, Coates JA (2022). Tracking changes between preprint posting and journal publication during a pandemic. PLoS Biology 20:e3001285. Research article doi:10.1371/journal.pbio.3001285 (opens an external site)
Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine 10:eaar7047. Research article doi:10.1126/scitranslmed.aar7047 (opens an external site)
Buzzi RM, Huber LC (2026). Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Reports 19:e276106. Research article doi:10.1136/bcr-2026-276106 (opens an external site)
Cardones AR, Grichnik JM (2009). alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Archives of Dermatology 145:441-444. Research article doi:10.1001/archdermatol.2008.623 (opens an external site)
Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, et al. (2026). Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. Rapid Communications in Mass Spectrometry 40:e70179. Research article doi:10.1002/rcm.70179 (opens an external site)
Cavasin MA, Rhaleb NE, Yang XP, Carretero OA (2004). Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43:1140-1145. Research article doi:10.1161/01.HYP.0000126172.01673.84 (opens an external site)
Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research 28:1155-1161. Research article doi:10.1002/jor.21107 (opens an external site)
Cha HJ, Jeong MJ, Kleinman HK (2003). Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute 95:1674-1680. Research article doi:10.1093/jnci/djg100 (opens an external site)
Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG (2004). Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291:2457-2465. Research article doi:10.1001/jama.291.20.2457 (opens an external site)
Chang CH, Tsai WC, Hsu YH, Pang JH (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 19:19066-19077. Research article doi:10.3390/molecules191119066 (opens an external site)
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology 110:774-780. Research article doi:10.1152/japplphysiol.00945.2010 (opens an external site)
Chege BM, Mwangi PW, Githinji CG, Bukachi F (2024). Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome. PLoS One 19:e0298752. Research article doi:10.1371/journal.pone.0298752 (opens an external site)
Choules MP, Bisson J, Simmler C, McAlpine JB, Giancaspro G, Bzhelyansky A, Niemitz M, Pauli GF (2020). NMR reveals an undeclared constituent in custom synthetic peptides. Journal of Pharmaceutical and Biomedical Analysis 178:112915. Research article doi:10.1016/j.jpba.2019.112915 (opens an external site)
Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA (2022). Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women's Health 31:171-182. Research article doi:10.1089/jwh.2021.0191 (opens an external site)
Cody WL, Wilkes BC, Muska BJ, Hruby VJ, Castrucci AM, Hadley ME (1984). Cyclic melanotropins. 5. Importance of the C-terminal tripeptide (Lys-Pro-Val). Journal of Medicinal Chemistry 27:1186-1190. Research article doi:10.1021/jm00375a018 (opens an external site)
Coelho SG, Yin L, Smuda C, Mahns A, Kolbe L, Hearing VJ (2015). Photobiological implications of melanin photoprotection after UVB-induced tanning of human skin but not UVA-induced tanning. Pigment Cell & Melanoma Research 28:210-216. Research article doi:10.1111/pcmr.12331 (opens an external site)
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism 18:3-14. Research article doi:10.1016/j.molmet.2018.09.009 (opens an external site)
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism 34:1234-1247.e9. Research article doi:10.1016/j.cmet.2022.07.013 (opens an external site)
Cousen P, Colver G, Helbling I (2009). Eruptive melanocytic naevi following melanotan injection. The British Journal of Dermatology 161:707-708. Research article doi:10.1111/j.1365-2133.2009.09362.x (opens an external site)
Cox HD, Miller GD, Eichner D (2017). Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Testing and Analysis 9:1490-1498. Research article doi:10.1002/dta.2152 (opens an external site)
Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D (2015). Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis 7:31-38. Research article doi:10.1002/dta.1715 (opens an external site)
Crockford D (2007). Development of thymosin beta4 for treatment of patients with ischemic heart disease. Annals of the New York Academy of Sciences 1112:385-395. Research article doi:10.1196/annals.1415.051 (opens an external site)
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 134:166-178. Research article doi:10.1053/j.gastro.2007.10.026 (opens an external site)
Darrow JJ, Avorn J, Kesselheim AS (2020). FDA Approval and Regulation of Pharmaceuticals, 1983-2018. JAMA 323:164-176. Research article doi:10.1001/jama.2019.20288 (opens an external site)
Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A (2017). Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 359:j4530. Research article doi:10.1136/bmj.j4530 (opens an external site)
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. (2004). Clinical trial registration: a statement from the International Committee of Medical Journal Editors. New England Journal of Medicine 351:1250-1251. Research article doi:10.1056/NEJMe048225 (opens an external site)
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995). Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131. Research article doi:10.2337/diab.44.9.1126 (opens an external site)
Deconinck E, Vanhee C, Keizers P, Guinot P, Mihailova A, Syversen PV, et al. (2021). The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study. Drug Testing and Analysis 13:833-840. Research article doi:10.1002/dta.3001 (opens an external site)
DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA (2016). Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Internal Medicine 176:1114-1122. Research article doi:10.1001/jamainternmed.2016.2765 (opens an external site)
Delcourt V, Garcia P, Chabot B, Aber N, Pescher M, et al. (2025). Equine Doping Controls of Thymosin β 4: A Population Study and Strategy for Misuse Detection. Drug Testing and Analysis 17:1071-1077. Research article doi:10.1002/dta.3806 (opens an external site)
Delcourt V, Garcia P, Chabot B, Barnabé A, Bouscarel M, et al. (2023). TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis 15:458-464. Research article doi:10.1002/dta.3421 (opens an external site)
Demirtaş H, Özer A, Yıldırım AK, Dursun AD, Sezen ŞC, Arslan M (2025). Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas) 61:291. Research article doi:10.3390/medicina61020291 (opens an external site)
Deville M, Charlier C (2024). Barbie drug identification: Not a child's play. Journal of Forensic Sciences 69:2331-2338. Research article doi:10.1111/1556-4029.15633 (opens an external site)
Devlin J, Pomerleau A, Foote J (2013). Melanotan II overdose associated with priapism. Clinical Toxicology 51:383. Research article doi:10.3109/15563650.2013.784775 (opens an external site)
DiMasi JA, Grabowski HG, Hansen RW (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 47:20-33. Research article doi:10.1016/j.jhealeco.2016.01.012 (opens an external site)
Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research 1117:54-60. Research article doi:10.1016/j.brainres.2006.07.108 (opens an external site)
Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry 97 Suppl 1:82-86. Research article doi:10.1111/j.1471-4159.2006.03658.x (opens an external site)
Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS (2012). Regulatory review of novel therapeutics--comparison of three regulatory agencies. New England Journal of Medicine 366:2284-2293. Research article doi:10.1056/NEJMsa1200223 (opens an external site)
Drazen JM, de Leeuw PW, Laine C, Mulrow C, DeAngelis CD, Frizelle FA, et al. (2010). Toward more uniform conflict disclosures — the updated ICMJE conflict of interest reporting form. New England Journal of Medicine 363:188-189. Research article doi:10.1056/NEJMe1006030 (opens an external site)
Dreyer BA, Amer T, Fraser M (2019). Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports 12. Research article doi:10.1136/bcr-2018-227644 (opens an external site)
du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S (1953). The synthesis of an octapeptide amide with the hormonal activity of oxytocin. Journal of the American Chemical Society 75:4879-4880. Research article doi:10.1021/ja01115a553 (opens an external site)
Dunn SP, Heidemann DG, Chow CY, Crockford D, Turjman N, et al. (2010). Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Annals of the New York Academy of Sciences 1194:199-206. Research article doi:10.1111/j.1749-6632.2010.05471.x (opens an external site)
Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, et al. (2010). Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. British Journal of Pharmacology 161:512-526. Research article doi:10.1111/j.1476-5381.2010.00922.x (opens an external site)
Eijmael MJPM, Janmaat CJ, Briët-Schipper EMN (2022). [The risks of tanning with the Barbie drug]. Nederlands Tijdschrift voor Geneeskunde 166:D6578. Research article PMID 35736369 (opens an external site)
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Journal of Biological Chemistry 267:7402-7405. Research article doi:10.1016/S0021-9258(18)42531-8 (opens an external site)
Eremin KO, Saransaari P, Oja S, Raevskiĭ KS (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Eksperimental'naia i Klinicheskaia Farmakologiia 67:8-11. Research article PMID 15188751 (opens an external site)
Errington TM, Mathur M, Soderberg CK, Denis A, Perfito N, Iorns E, Nosek BA (2021). Investigating the replicability of preclinical cancer biology. eLife 10:e71601. Research article doi:10.7554/eLife.71601 (opens an external site)
Esposito S, Deventer K, Geldof L, Van Eenoo P (2015). In vitro models for metabolic studies of small peptide hormones in sport drug testing. Journal of Peptide Science 21:1-9. Research article doi:10.1002/psc.2710 (opens an external site)
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis 4:733-738. Research article doi:10.1002/dta.1402 (opens an external site)
Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD (1997). Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385:165-168. Research article doi:10.1038/385165a0 (opens an external site)
Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P (2007). Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology 100:49-58. Research article doi:10.1111/j.1742-7843.2007.00008.x (opens an external site)
Freeman KW, Bowman BR, Zetter BR (2011). Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB Journal 25:907-915. Research article doi:10.1096/fj.10-169417 (opens an external site)
Friedman JM (2024). The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proceedings of the National Academy of Sciences of the United States of America 121:e2415550121. Research article doi:10.1073/pnas.2415550121 (opens an external site)
Froum S, Estrin N, Pico G, Yakubov M, Ahmad P, et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health 7:1907109. Research article doi:10.3389/froh.2026.1907109 (opens an external site)
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. (2020). Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5:e133429. Research article doi:10.1172/jci.insight.133429 (opens an external site)
Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, Dalsgaard PW, Reitzel LA, Linnet K (2019). Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Testing and Analysis 11:350-354. Research article doi:10.1002/dta.2489 (opens an external site)
Gautam D, Jeon J, Starost MF, Han SJ, Hamdan FF, Cui Y, Parlow AF, Gavrilova O, Szalayova I, Mezey E, Wess J (2009). Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proceedings of the National Academy of Sciences of the United States of America 106:6398-6403. Research article doi:10.1073/pnas.0900977106 (opens an external site)
Getting SJ, Schiöth HB, Perretti M (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics 306:631-637. Research article doi:10.1124/jpet.103.051623 (opens an external site)
Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F (1994). Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. The Journal of Clinical Endocrinology and Metabolism 78:693-698. Research article doi:10.1210/jcem.78.3.8126144 (opens an external site)
Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open 5:e2231982. Research article doi:10.1001/jamanetworkopen.2022.31982 (opens an external site)
Gilhooley E, Daly S, McKenna D (2021). Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology 237:995-999. Research article doi:10.1159/000514492 (opens an external site)
Goncharova ND, Khavinson BK, Lapin BA (2001). Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine 131:394-396. Research article doi:10.1023/a:1017928925177 (opens an external site)
Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in Aging Neuroscience 11:257. Research article doi:10.3389/fnagi.2019.00257 (opens an external site)
Greenberg SA (2009). How citation distortions create unfounded authority: analysis of a citation network. BMJ 339:b2680. Research article doi:10.1136/bmj.b2680 (opens an external site)
Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS (2009). Modulation of blood pressure by central melanocortinergic pathways. The New England Journal of Medicine 360:44-52. Research article doi:10.1056/NEJMoa0803085 (opens an external site)
Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG (2016). Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European Journal of Epidemiology 31:337-350. Research article doi:10.1007/s10654-016-0149-3 (opens an external site)
Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology 4:149-155. Research article doi:10.2147/JEP.S35396 (opens an external site)
Grillon C, Rieger K, Bakala J, Schott D, Morgat JL, et al. (1990). Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Letters 274:30-34. Research article doi:10.1016/0014-5793(90)81322-f (opens an external site)
Grudniewicz A, Moher D, Cobey KD, Bryson GL, Cukier S, Allen K, et al. (2019). Predatory journals: no definition, no defence. Nature 576:210-212. Research article doi:10.1038/d41586-019-03759-y (opens an external site)
Guerdjikova AI, Ward A, Ontiveros M, McElroy SL (2024). Semaglutide Misuse in Atypical Anorexia Nervosa-A Case Report. Journal of Clinical Psychopharmacology 44:179-180. Research article doi:10.1097/JCP.0000000000001820 (opens an external site)
Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB (1982). Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218:585-587. Research article doi:10.1126/science.6812220 (opens an external site)
Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 118:61-68. Research article doi:10.17116/jnevro20181183261-68 (opens an external site)
Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 97:26-34. Research article PMID 11517472 (opens an external site)
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, et al. (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-926. Research article doi:10.1136/bmj.39489.470347.AD (opens an external site)
Gyawali B, Hey SP, Kesselheim AS (2019). Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine 179:906-913. Research article doi:10.1001/jamainternmed.2019.0462 (opens an external site)
Hackam DG (2007). Translating animal research into clinical benefit. BMJ 334:163-164. Research article doi:10.1136/bmj.39104.362951.80 (opens an external site)
Hackam DG, Redelmeier DA (2006). Translation of research evidence from animals to humans. JAMA 296:1731-1732. Research article doi:10.1001/jama.296.14.1731 (opens an external site)
Haider MA, Javed H (2026). GLP-1 Receptor Agonists in Adolescents: Emerging Endocrine, Reproductive, and Psychosocial Concerns. Journal of Pediatric and Adolescent Gynecology. Research article doi:10.1016/j.jpag.2026.06.017 (opens an external site)
Hannappel E, van Kampen M (1987). Determination of thymosin beta 4 in human blood cells and serum. Journal of Chromatography 397:279-285. Research article doi:10.1016/s0021-9673(01)85010-x (opens an external site)
Haskell-Luevano C, Miwa H, Dickinson C, Hadley ME, Hruby VJ, Yamada T, Gantz I (1996). Characterizations of the unusual dissociation properties of melanotropin peptides from the melanocortin receptor, hMC1R. Journal of Medicinal Chemistry 39:432-435. Research article doi:10.1021/jm950407s (opens an external site)
Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW, et al. (2024). Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology 142:732-739. Research article doi:10.1001/jamaophthalmol.2024.2296 (opens an external site)
He L, Feng D, Guo H, Zhou Y, Li Z, et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology 13:1026182. Research article doi:10.3389/fphar.2022.1026182 (opens an external site)
Heerspink HJL, Lu Z, Du Y, Duffin KL, Coskun T, Haupt A, et al. (2025). The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney International Reports 10:1980-1992. Research article doi:10.1016/j.ekir.2025.03.049 (opens an external site)
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 142:5182-5189. Research article doi:10.1210/endo.142.12.8522 (opens an external site)
Henninge J, Pepaj M, Hullstein I, Hemmersbach P (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis 2:647-650. Research article doi:10.1002/dta.233 (opens an external site)
Hiltz ME, Lipton JM (1989). Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal 3:2282-2284. Research article PMID 2550304 (opens an external site)
Hitaka K, Sugawara T, Matsumoto M, Nio Y (2026). Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. International Journal of Obesity 50:928-937. Research article doi:10.1038/s41366-026-02025-2 (opens an external site)
Hjuler KF, Lorentzen HF (2014). Melanoma associated with the use of melanotan-II. Dermatology 228:34-36. Research article doi:10.1159/000356389 (opens an external site)
Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, et al. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A 1265:57-69. Research article doi:10.1016/j.chroma.2012.09.043 (opens an external site)
Holst JJ, Orskov C, Nielsen OV, Schwartz TW (1987). Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Letters 211:169-174. Research article doi:10.1016/0014-5793(87)81430-8 (opens an external site)
Hostynek JJ, Dreher F, Maibach HI (2011). Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research 60:79-86. Research article doi:10.1007/s00011-010-0238-9 (opens an external site)
Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977. Research article doi:10.1126/science.273.5277.974 (opens an external site)
Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Hadley ME, Cone RD (1995). Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. Journal of Medicinal Chemistry 38:3454-3461. Research article doi:10.1021/jm00018a005 (opens an external site)
Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports 10:17078. Research article doi:10.1038/s41598-020-74022-y (opens an external site)
Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine 95:323-333. Research article doi:10.1007/s00109-016-1488-y (opens an external site)
Huang HC, Hu CH, Tang MC, Wang WS, Chen PM, et al. (2007). Thymosin beta4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene 26:2781-2790. Research article doi:10.1038/sj.onc.1210078 (opens an external site)
Imazio M, Bobbio M, Broglio F, Benso A, Podio V, Valetto MR, Bisi G, Ghigo E, Trevi GP (2002). GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. European Journal of Heart Failure 4:185-191. Research article doi:10.1016/s1388-9842(01)00223-9 (opens an external site)
Ineichen BV, Furrer E, Grüninger SL, Zürrer WE, Macleod MR (2024). Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biology 22:e3002667. Research article doi:10.1371/journal.pbio.3002667 (opens an external site)
Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA (2008). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences 421:241-243. Research article doi:10.1134/s0012496608040066 (opens an external site)
Ioannidis JP (2005). Why most published research findings are false. PLoS Medicine 2:e124. Research article doi:10.1371/journal.pmed.0020124 (opens an external site)
Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ryzhak GA (2020). AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Advances in Gerontology (Uspekhi Gerontologii) 33:429-435. Research article PMID 33280326 (opens an external site)
Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG (2004). Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. International Journal of Pharmaceutics 276:75-81. Research article doi:10.1016/j.ijpharm.2004.02.012 (opens an external site)
Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta 188:795-807. Research article doi:10.1016/j.talanta.2018.06.023 (opens an external site)
Janvier S, Wattijn E, Botteldoorn N, De Spiegeleer B, Deconinck E, Vanhee C (2018). Are injectable illegal polypeptide drugs safe? Case report demonstrating the presence of haemolytic Bacillus cereus in 2 illegal peptide drugs. Drug Testing and Analysis 10:791-795. Research article doi:10.1002/dta.2304 (opens an external site)
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146:3052-3058. Research article doi:10.1210/en.2004-1286 (opens an external site)
Johansen PB, Hansen KT, Andersen JV, Johansen NL (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 28:1083-1092. Research article doi:10.1080/004982598238976 (opens an external site)
Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research 9:106-113. Research article doi:10.1054/ghir.1999.9998 (opens an external site)
Johnson IS (1983). Human insulin from recombinant DNA technology. Science 219:632-637. Research article doi:10.1126/science.6337396 (opens an external site)
Kadekaro AL, Kavanagh R, Kanto H, Terzieva S, Hauser J, Kobayashi N, Schwemberger S, Cornelius J, Babcock G, Shertzer HG, Scott G, Abdel-Malek ZA (2005). alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Research 65:4292-4299. Research article doi:10.1158/0008-5472.CAN-04-4535 (opens an external site)
Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Böhm M, Luger TA, Domschke W, Kucharzik T (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases 14:324-331. Research article doi:10.1002/ibd.20334 (opens an external site)
Kaski D, Stafford N, Mehta A, Jenkins IH, Malhotra P (2013). Melanotan and the posterior reversible encephalopathy syndrome. Annals of Internal Medicine 158:707-708. Research article doi:10.7326/0003-4819-158-9-201305070-00020 (opens an external site)
Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, et al. (2020). Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences of the United States of America 117:29959-29967. Research article doi:10.1073/pnas.2014879117 (opens an external site)
Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A (2002). Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters 23:365-368. Research article PMID 12195242 (opens an external site)
Khavinson VKh, Bondarev IE, Butyugov AA (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine 135:590-592. Research article doi:10.1023/a:1025493705728 (opens an external site)
Killion EA, Chen M, Falsey JR, Sivits G, Hager T, Atangan L, et al. (2020). Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nature Communications 11:4981. Research article doi:10.1038/s41467-020-18751-8 (opens an external site)
Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, et al. (2018). Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Science Translational Medicine 10:eaat3392. Research article doi:10.1126/scitranslmed.aat3392 (opens an external site)
Kingsberg SA, Clayton AH, Portman D, Krop J, Jordan R, Lucas J, Simon JA (2021). Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'". Journal of Sex Research 58:1106-1107. Research article doi:10.1080/00224499.2021.1902926 (opens an external site)
Klein NP, Edwards KM, Sparks RC, Dekker CL (2009). Recurrent sterile abscesses following aluminium adjuvant-containing vaccines. BMJ Case Reports 2009. Research article doi:10.1136/bcr.09.2008.0951 (opens an external site)
Klicek R, Sever M, Radic B, Drmic D, Kocman I, et al. (2008). Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. Journal of Pharmacological Sciences 108:7-17. Research article doi:10.1254/jphs.fp0072161 (opens an external site)
Knoop A, Thomas A, Thevis M (2019). Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry 33:371-380. Research article doi:10.1002/rcm.8337 (opens an external site)
Knudsen LB (2024). GLP-1 for Treating Obesity-Origin, History, and Evolution: 2024 Lasker-DeBakey Clinical Medical Research Award. JAMA. Research article doi:10.1001/jama.2024.18000 (opens an external site)
Kobayashi T, Okada F, Fujii N, Tomita N, Ito S, et al. (2002). Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells. American Journal of Pathology 160:869-882. Research article doi:10.1016/s0002-9440(10)64910-3 (opens an external site)
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660. Research article doi:10.1038/45230 (opens an external site)
Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N (2011). Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides 170:18-23. Research article doi:10.1016/j.regpep.2011.05.001 (opens an external site)
Koroleva MV, Meĭzerov EE, Nezavibat'ko VN, Kamenskiĭ AA, Dubynin VA, Iakovlev IuB (1996). Study of the analgesic effect of the semax preparation. Biulleten' Eksperimental'noi Biologii i Meditsiny 122:527-529. Research article PMID 8998343 (opens an external site)
Kreymann B, Williams G, Ghatei MA, Bloom SR (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. The Lancet 2:1300-1304. Research article doi:10.1016/s0140-6736(87)91194-9 (opens an external site)
Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, Sickmann A, Thevis M (2018). Analysis of new growth promoting black market products. Growth Hormone & IGF Research 41:1-6. Research article doi:10.1016/j.ghir.2018.05.001 (opens an external site)
Krug O, Thomas A, Walpurgis K, Piper T, Sigmund G, Schänzer W, Laussmann T, Thevis M (2014). Identification of black market products and potential doping agents in Germany 2010-2013. European Journal of Clinical Pharmacology 70:1303-1311. Research article doi:10.1007/s00228-014-1743-5 (opens an external site)
Kwok WH, Ho EN, Lau MY, Leung GN, Wong AS, et al. (2013). Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry 405:2595-2606. Research article doi:10.1007/s00216-012-6697-9 (opens an external site)
Kwon DR, Park GY (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science 45:426-432. Research article PMID 26275694 (opens an external site)
Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications 280:132-138. Research article doi:10.1006/bbrc.2000.4065 (opens an external site)
Lambson JE, Flegal SC, Johnson AR (2023). Administration errors of compounded semaglutide reported to a poison control center-Case series. Journal of the American Pharmacists Association 63:1643-1645. Research article doi:10.1016/j.japh.2023.06.017 (opens an external site)
Land SC (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology 4:59-73. Research article PMID 22837805 (opens an external site)
Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A (1995). Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clinical Endocrinology 43:631-635. Research article doi:10.1111/j.1365-2265.1995.tb02929.x (opens an external site)
Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 138:843-853.e1-2. Research article doi:10.1053/j.gastro.2009.11.003 (opens an external site)
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry 58:7370-7380. Research article doi:10.1021/acs.jmedchem.5b00726 (opens an external site)
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 21:443-454. Research article doi:10.1016/j.cmet.2015.02.009 (opens an external site)
Lee E, Burgess K (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine 31:20-24. Research article PMID 40131143 (opens an external site)
Lee E, Padgett B (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine 27:8-13. Research article PMID 34324435 (opens an external site)
Lee E, Walker C, Ayadi B (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine 30:12-17. Research article PMID 39325560 (opens an external site)
Li H, Toh PZ, Tan JY, Zin MT, Lee CY, Li B, Leolukman M, Bao H, Kang L (2016). Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Scientific Reports 6:37664. Research article doi:10.1038/srep37664 (opens an external site)
Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery 10:77. Research article doi:10.1038/s41421-024-00700-0 (opens an external site)
Low TL, Hu SK, Goldstein AL (1981). Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proceedings of the National Academy of Sciences of the United States of America 78:1162-1166. Research article doi:10.1073/pnas.78.2.1162 (opens an external site)
Lu H, Wei M, Zhai Y, Li Q, Ye Z, Wang L, Luo W, Chen J, Lu Z (2019). MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of Molecular Medicine (Berlin) 97:473-485. Research article doi:10.1007/s00109-018-01738-w (opens an external site)
Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, et al. (2015). Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biology 13:e1002273. Research article doi:10.1371/journal.pbio.1002273 (opens an external site)
Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology 113:364-368. Research article doi:10.1046/j.1523-1747.1999.00708.x (opens an external site)
Mallory CW, Lopategui DM, Cordon BH (2021). Melanotan Tanning Injection: A Rare Cause of Priapism. Sexual Medicine 9:100298. Research article doi:10.1016/j.esxm.2020.100298 (opens an external site)
Malmlöf K, Johansen PB, Haahr PM, Wilken M, Oxlund H (1999). Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth Hormone & IGF Research 9:445-450. Research article doi:10.1054/ghir.1999.0128 (opens an external site)
Mandrika I, Muceniece R, Wikberg JE (2001). Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. Biochemical Pharmacology 61:613-621. Research article doi:10.1016/s0006-2952(00)00583-9 (opens an external site)
Mang R, Krahl D, Assmann T (2012). [Dermoscopic changes in melanocytic nevi during use of melanotan II]. Der Hautarzt 63:880-884. Research article doi:10.1007/s00105-012-2420-1 (opens an external site)
Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, Monboisse JC, Chastang F, Birembaut P, Gillery P, et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of Clinical Investigation 92:2368-2376. Research article doi:10.1172/JCI116842 (opens an external site)
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters 238:343-346. Research article doi:10.1016/0014-5793(88)80509-x (opens an external site)
Maric T, Bazhin A, Khodakivskyi P, Mikhaylov G, Solodnikova E, Yevtodiyenko A, et al. (2023). A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD(+) metabolism. Biosensors and Bioelectronics 220:114826. Research article doi:10.1016/j.bios.2022.114826 (opens an external site)
Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV (1971). Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochemical and Biophysical Research Communications 43:1334-1339. Research article doi:10.1016/s0006-291x(71)80019-0 (opens an external site)
Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, Evans RM (1988). Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Molecular Endocrinology 2:606-612. Research article doi:10.1210/mend-2-7-606 (opens an external site)
McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY, et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety 25:581-588. Research article doi:10.1080/14740338.2025.2499670 (opens an external site)
Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF (2014). A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 114:17-22. Research article PMID 25176261 (opens an external site)
Medvedev VE, Tereshchenko ON, Kost NV, Ter-Israelyan AY, Gushanskaya EV, Chobanu IK, Sokolov OY, Myasoedov NF (2015). Optimization of the treatment of anxiety disorders with selank. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 115:33-40. Research article doi:10.17116/jnevro20151156133-40 (opens an external site)
Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis 13:1871-1887. Research article doi:10.1002/dta.3183 (opens an external site)
Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis 13:1871-1887. Research article doi:10.1002/dta.3183 (opens an external site)
Merrifield RB (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society 85:2149-2154. Research article doi:10.1021/ja00897a025 (opens an external site)
Mestria S, Odoardi S, Frison G, Strano Rossi S (2021). LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. Drug Testing and Analysis 13:876-882. Research article doi:10.1002/dta.2986 (opens an external site)
Miller TR, Wagner JD, Baack BR, Eisbach KJ (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery 8:252-259. Research article doi:10.1001/archfaci.8.4.252 (opens an external site)
Mojsov S, Weir GC, Habener JF (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation 79:616-619. Research article doi:10.1172/JCI112855 (opens an external site)
Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences 994:96-102. Research article doi:10.1111/j.1749-6632.2003.tb03167.x (opens an external site)
Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair and Regeneration 2:259-269. Research article doi:10.1046/j.1524-475X.1994.20406.x (opens an external site)
Murad MH, Asi N, Alsawas M, Alahdab F (2016). New evidence pyramid. Evidence-Based Medicine 21:125-127. Research article doi:10.1136/ebmed-2016-110401 (opens an external site)
Nakazzi F, Zarei M, Lopes M, Graor HJ, Beegan WC, Gu E, et al. (2026). Vitamin B3 derivatives support pancreatic cancer cell survival and chemotherapy resistance. Cancer Letters 645:218334. Research article doi:10.1016/j.canlet.2026.218334 (opens an external site)
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 91:301-307. Research article doi:10.1172/JCI116186 (opens an external site)
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993). Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744. Research article doi:10.1007/BF00401145 (opens an external site)
Nelson ME, Bryant SM, Aks SE (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology 50:1169-1173. Research article doi:10.3109/15563650.2012.740637 (opens an external site)
Neumann J, Ahlrep U, Hofmann B, Gergs U (2025). Contractile effects of retatrutide in isolated mouse atrial preparations. Naunyn-Schmiedeberg's Archives of Pharmacology 398:17147-17160. Research article doi:10.1007/s00210-025-04335-0 (opens an external site)
Neumann J, Ahlrep U, Hofmann B, Gergs U (2026). Inotropic effects of retatrutide in isolated human atrial preparations. Naunyn-Schmiedeberg's Archives of Pharmacology 399:317-327. Research article doi:10.1007/s00210-025-04421-3 (opens an external site)
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research 53:274-278. Research article doi:10.1159/000053183 (opens an external site)
Ong S, Bowling J (2012). Melanotan-associated melanoma in situ. The Australasian Journal of Dermatology 53:301-302. Research article doi:10.1111/j.1440-0960.2012.00915.x (opens an external site)
Ou H, Chen R, Zhou L, Zhang Y, Zhao S, Yang Z (2026). Thymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5 × FAD mice: A potential therapy for memory improvement in Alzheimer's disease. International Immunopharmacology 170:116097. Research article doi:10.1016/j.intimp.2025.116097 (opens an external site)
Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbjörnsdottir S, Jonasson C, et al. (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ 385:e078225. Research article doi:10.1136/bmj-2023-078225 (opens an external site)
Paurobally D, Jason F, Dezfoulian B, Nikkels AF (2011). Melanotan-associated melanoma. The British Journal of Dermatology 164:1403-1405. Research article doi:10.1111/j.1365-2133.2011.10273.x (opens an external site)
Pawar K, Kolli CS, Rangari VK, Babu RJ (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences 106:1814-1820. Research article doi:10.1016/j.xphs.2017.03.017 (opens an external site)
Peters B, Hadimeri H, Wahlberg R, Afghahi H (2020). Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Reports 9:159-161. Research article doi:10.1007/s13730-020-00447-z (opens an external site)
Pfaus J, Giuliano F, Gelez H (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. The Journal of Sexual Medicine 4 Suppl 4:269-279. Research article doi:10.1111/j.1743-6109.2007.00610.x (opens an external site)
Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America 101:10201-10204. Research article doi:10.1073/pnas.0400491101 (opens an external site)
Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration 11:19-24. Research article doi:10.1046/j.1524-475x.2003.11105.x (opens an external site)
Piatkowski T, Craven A, Cornell S, Ferris J (2026). Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug and Alcohol Review 45:e70231. Research article doi:10.1111/dar.70231 (opens an external site)
Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B (1980). Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature 288:715-717. Research article doi:10.1038/288715a0 (opens an external site)
Pickart L, Thaler MM (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature: New Biology 243:85-87. Research article PMID 4349963 (opens an external site)
Pope HG Jr, Kanayama G, Ionescu-Pioggia M, Hudson JI (2004). Anabolic steroid users' attitudes towards physicians. Addiction 99:1189-1194. Research article doi:10.1111/j.1360-0443.2004.00781.x (opens an external site)
Rahaman KA, Muresan AR, Min H, Son J, Han HS, et al. (2024). Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 1235:124033. Research article doi:10.1016/j.jchromb.2024.124033 (opens an external site)
Rahim A, O'Neill PA, Shalet SM (1998). Growth hormone status during long-term hexarelin therapy. The Journal of Clinical Endocrinology and Metabolism 83:1644-1649. Research article doi:10.1210/jcem.83.5.4812 (opens an external site)
Rahim A, O'Neill PA, Shalet SM (1999). The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clinical Endocrinology 50:77-84. Research article doi:10.1046/j.1365-2265.1999.00609.x (opens an external site)
Rahim A, Shalet SM (1998). Does desensitization to hexarelin occur?. Growth Hormone & IGF Research 8 Suppl B:141-143. Research article doi:10.1016/s1096-6374(98)80039-7 (opens an external site)
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 139:552-561. Research article doi:10.1530/eje.0.1390552 (opens an external site)
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications 12:470. Research article doi:10.1038/s41467-020-20790-0 (opens an external site)
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. (2024). Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Internal Medicine 184:1056-1064. Research article doi:10.1001/jamainternmed.2024.2525 (opens an external site)
Rogozinskaya EY, Lyapina MG (2017). Anticoagulant Effects of Arginine-Containing Peptides of the Glyproline Family (His-Phe-Arg-Trp-Pro-Gly-Pro and Thr-Lys-Pro-Arg-Pro-Gly-Pro) Revealed by Thromboelastography. Bulletin of Experimental Biology and Medicine 164:170-172. Research article doi:10.1007/s10517-017-3950-4 (opens an external site)
Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, Di Francesco P, Garaci E (2004). Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103:4232-4239. Research article doi:10.1182/blood-2003-11-4036 (opens an external site)
Ross JS, Hill KP, Egilman DS, Krumholz HM (2008). Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 299:1800-1812. Research article doi:10.1001/jama.299.15.1800 (opens an external site)
Rubin R (2026). Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. JAMA. Research article doi:10.1001/jama.2026.20514 (opens an external site)
Ryle AP, Sanger F, Smith LF, Kitai R (1955). The disulphide bonds of insulin. Biochemical Journal 60:541-556. Research article doi:10.1042/bj0600541 (opens an external site)
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research 19:471-477. Research article doi:10.1016/j.ghir.2009.03.001 (opens an external site)
Safarinejad MR (2008). RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. The Journal of Sexual Medicine 5:887-897. Research article doi:10.1111/j.1743-6109.2007.00698.x (opens an external site)
Safarinejad MR, Hosseini SY (2023). Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. The Journal of Urology. Research article doi:10.1097/JU.0000000000003117 (opens an external site)
Safer D, Elzinga M, Nachmias VT (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry 266:4029-4032. Research article PMID 1999398 (opens an external site)
Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, et al. (2016). Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes, Obesity and Metabolism 18:72-81. Research article doi:10.1111/dom.12585 (opens an external site)
Samms RJ, Christe ME, Collins KA, Pirro V, Droz BA, Holland AK, et al. (2021). GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation 131:e146353. Research article doi:10.1172/JCI146353 (opens an external site)
Santiago M, Davis EA, Hinton T, Angelo TA, Shield A, Babey AM, et al. (2021). Defining and unpacking the core concepts of pharmacology education. Pharmacology Research & Perspectives 9:e00894. Research article doi:10.1002/prp2.894 (opens an external site)
Schlesinger DH, Pickart L, Thaler MM (1977). Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia 33:324-325. Research article doi:10.1007/BF02002806 (opens an external site)
Schulze F, Erdmann H, Hardkop LH, Anemüller W, Rose C, Zillikens D, Fischer TW (2014). Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. European Journal of Dermatology 24:107-109. Research article doi:10.1684/ejd.2013.2227 (opens an external site)
Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. (2008). Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis 9:4-15. Research article doi:10.1080/17482960701856300 (opens an external site)
Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC (2026). Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Network Open 9:e2638929. Research article doi:10.1001/jamanetworkopen.2026.38929 (opens an external site)
Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Testing and Analysis 7:919-925. Research article doi:10.1002/dta.1787 (opens an external site)
Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR (2010). Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biology 8:e1000344. Research article doi:10.1371/journal.pbio.1000344 (opens an external site)
Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America 110:3507-3512. Research article doi:10.1073/pnas.1222878110 (opens an external site)
Shah R, Reyes-Gordillo K, Rojkind M (2018). Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opinion on Biological Therapy 18:177-184. Research article doi:10.1080/14712598.2018.1478961 (opens an external site)
Shamseer L, Moher D, Maduekwe O, Turner L, Barbour V, Burch R, et al. (2017). Potential predatory and legitimate biomedical journals: can you tell the difference? A cross-sectional comparison. BMC Medicine 15:28. Research article doi:10.1186/s12916-017-0785-9 (opens an external site)
Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, et al. (1997). The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology 332:23-33. Research article doi:10.1016/s0014-2999(97)01033-9 (opens an external site)
Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, et al. (2025). BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel) 18. Research article doi:10.3390/ph18101450 (opens an external site)
Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445:177-182. Research article doi:10.1038/nature05383 (opens an external site)
Smith RM, Schaefer MK, Kainer MA, Wise M, Finks J, et al. (2013). Fungal infections associated with contaminated methylprednisolone injections. The New England Journal of Medicine 369:1598-1609. Research article doi:10.1056/NEJMoa1213978 (opens an external site)
Stammers J, Hofste Op Bruinink D, Karel PGA, van der Hoeven CJ, Schol-Gelok S, Stam-Slob MC (2026). Insulin intoxications caused by falsified semaglutide. Nederlands Tijdschrift voor Geneeskunde 170:D9116. Research article PMID 42390457 (opens an external site)
Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. The Journal of Clinical Endocrinology and Metabolism 96:150-158. Research article doi:10.1210/jc.2010-1587 (opens an external site)
Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research 21:976-983. Research article doi:10.1016/S0736-0266(03)00110-4 (opens an external site)
Stier H, Vos E, Kenley D (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism 3:7-15. Research article doi:10.4021/jem157w (opens an external site)
Sumner P, Vivian-Griffiths S, Boivin J, Williams A, Venetis CA, Davies A, et al. (2014). The association between exaggeration in health related science news and academic press releases: retrospective observational study. BMJ 349:g7015. Research article doi:10.1136/bmj.g7015 (opens an external site)
Sung J, Ju SY, Park S, Jung WK, Je JY, Lee SJ (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue & Cell 95:102837. Research article doi:10.1016/j.tice.2025.102837 (opens an external site)
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine 355:1018-1028. Research article doi:10.1056/NEJMoa063842 (opens an external site)
Supersaxo A, Hein WR, Steffen H (1990). Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharmaceutical Research 7:167-169. Research article doi:10.1023/a:1015880819328 (opens an external site)
Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of Endocrinology 165:569-577. Research article doi:10.1677/joe.0.1650569 (opens an external site)
Takahashi M, Abe I, Yoshida N, Katoh D, Fujita D, Goto S, et al. (2026). Kynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation. Nature Communications 17:6616. Research article doi:10.1038/s41467-026-72974-9 (opens an external site)
Takao K, Miyakawa T (2015). Genomic responses in mouse models greatly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America 112:1167-1172. Research article doi:10.1073/pnas.1401965111 (opens an external site)
Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, et al. (2000). Ghrelin strongly stimulates growth hormone release in humans. The Journal of Clinical Endocrinology and Metabolism 85:4908-4911. Research article doi:10.1210/jcem.85.12.7167 (opens an external site)
Thorner MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, Johanson A, Vale W, Horvath E, Kovacs K (1982). Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. The Journal of Clinical Investigation 70:965-977. Research article doi:10.1172/jci110708 (opens an external site)
Timms M, Ganio K, Forbes G, Bailey S, Steel R (2019). An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Testing and Analysis 11:804-812. Research article doi:10.1002/dta.2554 (opens an external site)
Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, Hjalmarson A, Bengtsson BA, Isgaard J (2000). The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 141:60-66. Research article doi:10.1210/endo.141.1.7249 (opens an external site)
Tkalcević VI, Cuzić S, Brajsa K, Mildner B, Bokulić A, et al. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European Journal of Pharmacology 570:212-221. Research article doi:10.1016/j.ejphar.2007.05.072 (opens an external site)
Trivedi P, Jiang M, Tamvakopoulos CC, Shen X, Yu H, Mock S, Fenyk-Melody J, Van der Ploeg LH, Guan XM (2003). Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain Research 977:221-230. Research article doi:10.1016/s0006-8993(03)02683-0 (opens an external site)
Urva S, O'Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, et al. (2023). The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism 25:2784-2788. Research article doi:10.1111/dom.15167 (opens an external site)
Vadner DJ, Smith S (2026). Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. JAAD Case Reports 73:111-114. Research article doi:10.1016/j.jdcr.2026.05.009 (opens an external site)
van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR (2010). Can animal models of disease reliably inform human studies?. PLoS Medicine 7:e1000245. Research article doi:10.1371/journal.pmed.1000245 (opens an external site)
Vanhee C, Francotte A, Janvier S, Deconinck E (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis 12:371-381. Research article doi:10.1002/dta.2717 (opens an external site)
Vanhee C, Janvier S, Moens G, Goscinny S, Courselle P, Deconinck E (2017). Identification of epidermal growth factor (EGF), in an unknown pharmaceutical preparation suspected to contain insulin like growth factor 1 (IGF-1). Drug Testing and Analysis 9:831-837. Research article doi:10.1002/dta.2029 (opens an external site)
Vanhee C, Moens G, Deconinck E, De Beer JO (2014). Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. Drug Testing and Analysis 6:964-968. Research article doi:10.1002/dta.1687 (opens an external site)
Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO (2015). Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations. Drug Testing and Analysis 7:259-264. Research article doi:10.1002/dta.1771 (opens an external site)
Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A (1995). BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. Journal of Pharmacology and Experimental Therapeutics 272:417-422. Research article PMID 7815358 (opens an external site)
Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of Pharmacology and Experimental Therapeutics 329:1110-1116. Research article doi:10.1124/jpet.108.149211 (opens an external site)
Verbaanderd C, Rooman I, Huys I (2021). Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research. Trials 22:322. Research article doi:10.1186/s13063-021-05273-x (opens an external site)
Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology 2:340-357. Research article doi:10.1016/j.jcmgh.2016.01.006 (opens an external site)
Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, et al. (2018). Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism 20:889-897. Research article doi:10.1111/dom.13172 (opens an external site)
Wang AT, McCoy CP, Murad MH, Montori VM (2010). Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 340:c1344. Research article doi:10.1136/bmj.c1344 (opens an external site)
Wang WS, Chen PM, Hsiao HL, Wang HS, Liang WY, et al. (2004). Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 23:6666-6671. Research article doi:10.1038/sj.onc.1207888 (opens an external site)
Weber C, Krug O, Kamber M, Thevis M (2017). Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border. Substance Use & Misuse 52:742-753. Research article doi:10.1080/10826084.2016.1263665 (opens an external site)
Wen Y, Lemen D, Lin Y, Chen YQ, Regmi A, Roell WC, et al. (2025). Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes, Obesity and Metabolism 27:5985-5995. Research article doi:10.1111/dom.16661 (opens an external site)
Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW (2003). Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience 118:755-762. Research article doi:10.1016/s0306-4522(02)00866-7 (opens an external site)
White WB, Myers MG, Jordan R, Lucas J (2017). Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Journal of Hypertension 35:761-768. Research article doi:10.1097/HJH.0000000000001221 (opens an external site)
Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5:e140532. Research article doi:10.1172/jci.insight.140532 (opens an external site)
Wislar JS, Flanagin A, Fontanarosa PB, Deangelis CD (2011). Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ 343:d6128. Research article doi:10.1136/bmj.d6128 (opens an external site)
Wong CH, Siah KW, Lo AW (2019). Estimation of clinical trial success rates and related parameters. Biostatistics 20:273-286. Research article doi:10.1093/biostatistics/kxx069 (opens an external site)
Wouters OJ, McKee M, Luyten J (2020). Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA 323:844-853. Research article doi:10.1001/jama.2020.1166 (opens an external site)
Wu JC, Tsai HE, Hsiao YH, Wu JS, Wu CS, Tai MH (2020). Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International Journal of Molecular Sciences 21:681. Research article doi:10.3390/ijms21020681 (opens an external site)
Wyczółkowska J, Walczak-Drzewiecka A, Wagner W, Dastych J (2007). Thymosin beta4 and thymosin beta4-derived peptides induce mast cell exocytosis. Peptides 28:752-759. Research article doi:10.1016/j.peptides.2007.01.004 (opens an external site)
Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy 25:1628-1640. Research article doi:10.1016/j.ymthe.2016.11.020 (opens an external site)
Xu C, Sun L, Ren F, Huang P, Tian Z, et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology 114:104665. Research article doi:10.1016/j.yrtph.2020.104665 (opens an external site)
Yassin Alsabbagh A, Bhujel N, Singh RP (2025). Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. International Journal of Oral and Maxillofacial Surgery 54:806-808. Research article doi:10.1016/j.ijom.2025.03.014 (opens an external site)
Yavchitz A, Boutron I, Bafeta A, Marroun I, Charles P, Mantz J, Ravaud P (2012). Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Medicine 9:e1001308. Research article doi:10.1371/journal.pmed.1001308 (opens an external site)
Yildirim AK, Dastan AO, Demeli Ertus M, Ensarioglu M, Karabacak K, Pehlivanoglu B (2026). Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine 15:3488. Research article doi:10.3390/jcm15093488 (opens an external site)
Yoon HJ, Oh YL, Ko EJ, Kang A, Eo WK, et al. (2021). Effects of thymosin β4-derived peptides on migration and invasion of ovarian cancer cells. Genes & Genomics 43:987-993. Research article doi:10.1007/s13258-021-01127-7 (opens an external site)
Young AR (2020). Comparison of Skin Photoprotection by Pigmentation and Sunscreens. Journal of Cosmetic Science 71:217-226. Research article PMID 33022206 (opens an external site)
Zhang H, Chen LN, Yang D, Mao C, Shen Q, Feng W, Shen DD, Dai A, Xie S, Zhou Y, Qin J, Sun JP, Scharf DH, Hou T, Zhou T, Wang MW, Zhang Y (2021). Structural insights into ligand recognition and activation of the melanocortin-4 receptor. Cell Research 31:1163-1175. Research article doi:10.1038/s41422-021-00552-3 (opens an external site)
Zhang J, Liu M, Ou H, Wang Z, He L, et al. (2026). BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Communication and Signaling 24. Research article doi:10.1186/s12964-026-02694-6 (opens an external site)
Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, et al. (2021). The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metabolism 33:833-844.e5. Research article doi:10.1016/j.cmet.2021.01.015 (opens an external site)
Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. The Journal of Biological Chemistry 279:34682-34690. Research article doi:10.1074/jbc.M402999200 (opens an external site)
Zinzi A, Gaio M, Ruggiero R, Mascolo A, Riemma MA, Cipriani M, Laino LV, Berrino L, Rossi F, Capuano A (2026). Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Frontiers in Pharmacology 17:1805842. Research article doi:10.3389/fphar.2026.1805842 (opens an external site)
Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 108:38-48. Research article PMID 18454096 (opens an external site)
Zozulya AA, Kost NV, Yu Sokolov O, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine 131:315-317. Research article doi:10.1023/a:1017979514274 (opens an external site)
Zvereva I, Semenistaya E, Krotov G, Rodchenkov G (2016). Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. Journal of Proteomics 149:85-97. Research article doi:10.1016/j.jprot.2016.08.016 (opens an external site)

Trial registration (54)

ClinicalTrials.gov (2006). NCT00267527: A multicenter, randomized, placebo-controlled, double-blind, phase 2 study to evaluate the efficacy and safety of CJC 1295 administered for 12 weeks in HIV infected patients with HIV associated visceral obesity. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
ClinicalTrials.gov (2009). NCT00672074 — A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
ClinicalTrials.gov (2010). NCT00382174: Thymosin beta 4 in patients with pressure ulcers (phase 2, RegeneRx), results posted. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2010). NCT00832091: Thymosin beta 4 in patients with venous stasis ulcers (phase 2, RegeneRx with sigma-tau), results posted. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2014). NCT01280344 — Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
ClinicalTrials.gov (2014). NCT00311766: Thymosin beta 4 for wound healing in epidermolysis bullosa (phase 2, RegeneRx), results posted. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2015). NCT02637284 — Phase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02, which active ingredient is BPC-157. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2015). NCT00598871: Thymosin beta 4 eye drops for corneal wounds in diabetic patients after vitrectomy (phase 2), results posted. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2016). NCT02668055: Slow-release Tβ4 collagen and chitosan sponge skin substitute for difficult-to-heal wounds (phase 1, Chinese PLA General Hospital). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2019). NCT03998514 — A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
ClinicalTrials.gov (2019). NCT02597803: ARISE-1, RGN-259 ophthalmic solution for dry eye (phase 2/3, ReGenTree). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2021). NCT01311518: RGN-352 (injectable thymosin beta 4) in acute ST-elevation myocardial infarction (phase 2, RegeneRx). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2022). NCT02974907: ARISE-2, RGN-259 ophthalmic solution for dry eye (phase 3, ReGenTree), results posted. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2022). NCT03578029: CELEB, RGN-137 topical gel in junctional and dystrophic epidermolysis bullosa (phase 2, Lenus Therapeutics). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2022). NCT05485818: Phase IIa study of injectable recombinant human thymosin beta 4 in acute myocardial infarction (Beijing Northland Biotech). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2023). NCT02600429: SEER-1, RGN-259 for neurotrophic keratopathy (phase 3, ReGenTree), results posted. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2024). NCT05984134: Phase IIb study of recombinant human thymosin β4 (NL005) in acute myocardial infarction (Beijing Northland Biotech). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2025). NCT07752381 — A clinical trial to evaluate the effects of peptide gummies on markers of inflammation, physical performance, and recovery. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2025). NCT05555589: SEER-2, 0.1% RGN-259 for neurotrophic keratopathy (phase 3, ReGenTree). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07437547 — A randomized, double-blind, placebo-controlled phase 2 trial of pentadecapeptide BPC 157 for accelerated repair of acute grade II hamstring strain confirmed by MRI. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07803250 — Impact of BPC-157 on recovery from rotator cuff repair surgery. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07717866 — Trifecta Research Study: an observational study evaluating ibogaine-magnesium, 5-MeO-DMT, magnetic e-resonance therapy and physiological supplementation in Special Operations Forces combat veterans. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
ClinicalTrials.gov (2026). NCT03841630 — A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT04881760 — A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (results). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT04867785 — A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes (results). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT05929066 — A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT05882045 — A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT05931367 — A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT06260722 — A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT06662383 — A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT06383390 — A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH-Outcomes). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07165028 — A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT06313528 — A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT06039826 — A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT05445232 — A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07629401 — Pre-approval Expanded Access of Retatrutide (LY3437943). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). ClinicalTrials.gov search, 20 October 2026: intervention 'retatrutide OR LY3437943' — 34 records. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07505745 — A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity (MOTS-MET). Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
ClinicalTrials.gov (2026). NCT03937882: ARISE-3, RGN-259 ophthalmic solution for dry eye (phase 3, ReGenTree), results posted. Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07586865: Phase IIc study of recombinant human thymosin beta 4 injection (NL005) in acute myocardial infarction (Beijing Northland Biotech). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (2026). NCT07487363: 'TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD' (TBRIDGE-CV). Trial registration clinicaltrials.gov (opens an external site) — accessed 20 October 2026
ClinicalTrials.gov (U.S. National Library of Medicine) (2026). NCT07437560: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Melanotan II as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
EU Clinical Trials Register (2005). EudraCT 2005-003797-25: A multicenter, randomized, placebo-controlled, double-blind phase 2 study to evaluate the efficacy and safety of CJC-1295 (Germany). Trial registration clinicaltrialsregister.eu (opens an external site) — accessed 22 October 2026
European Parliament, Legislative Observatory (2026). Procedure file 2023/0132(COD): Medicinal products for human use (Directive, repealing Directive 2001/83/EC). Trial registration oeil.secure.europarl.europa.eu (opens an external site) — accessed 22 October 2026
European Parliament, Legislative Observatory (2026). Procedure file 2023/0131(COD): Union procedures for the authorisation and supervision of medicinal products for human use and rules governing the European Medicines Agency (Regulation). Trial registration oeil.secure.europarl.europa.eu (opens an external site) — accessed 22 October 2026
Massachusetts General Hospital (2026). Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (NCT06554717). ClinicalTrials.gov. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
Theratechnologies (2018). Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® (NCT01591902). ClinicalTrials.gov. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
Theratechnologies (2018). Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® (NCT01579695). ClinicalTrials.gov. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
U.S. National Library of Medicine (2026). ClinicalTrials.gov: studies with the intervention bremelanotide or PT-141 (search run 22 October 2026). ClinicalTrials.gov. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
U.S. National Library of Medicine, ClinicalTrials.gov (2026). ClinicalTrials.gov API v2 searches: trials of BPC-157 and other peptides on this site with a site in the Netherlands or Belgium. Trial registration clinicaltrials.gov (opens an external site) — accessed 22 October 2026
U.S. National Library of Medicine, ClinicalTrials.gov (2026). NCT07437586: Topical GHK-Cu gel to accelerate re-epithelialisation of standardised acute skin wounds in healthy adults (phase 2, randomised, double-blind, vehicle-controlled, split-wound). Trial registration clinicaltrials.gov (opens an external site) — accessed 23 October 2026
U.S. National Library of Medicine, ClinicalTrials.gov (2026). NCT01572909: EMBRACE STEMI, phase 2a trial of intravenous MTP-131 (elamipretide) on reperfusion injury. Trial registration clinicaltrials.gov (opens an external site) — accessed 23 October 2026
U.S. National Library of Medicine, ClinicalTrials.gov (2026). NCT07531251: Phase 3b/4 randomised, double-blind, placebo-controlled trial of daily subcutaneous elamipretide in genetically confirmed Barth syndrome. Trial registration clinicaltrials.gov (opens an external site) — accessed 23 October 2026
U.S. National Library of Medicine, ClinicalTrials.gov (2026). NCT06373731: ReNEW, phase 3 double-masked placebo-controlled trial of subcutaneous elamipretide in dry age-related macular degeneration. Trial registration clinicaltrials.gov (opens an external site) — accessed 23 October 2026

Report (10)

CohBar, Inc. (2021). Press release dated August 10, 2021: topline results from the Phase 1a/1b study of CB4211 (Exhibit 99.2 to Form 8-K). U.S. Securities and Exchange Commission, EDGAR. Report sec.gov (opens an external site) — accessed 22 October 2026
CohBar, Inc. (2021). Q2 Investor Presentation, August 2021 (Exhibit 99.3 to Form 8-K). U.S. Securities and Exchange Commission, EDGAR. Report sec.gov (opens an external site) — accessed 22 October 2026
CohBar, Inc. (2023). Form S-4 Registration Statement, filed 3 July 2023. U.S. Securities and Exchange Commission, EDGAR. Report sec.gov (opens an external site) — accessed 22 October 2026
CohBar, Inc. (2023). Form 8-K Current Report, filed 1 November 2023 (termination of merger agreement; intention to liquidate and dissolve). U.S. Securities and Exchange Commission, EDGAR. Report sec.gov (opens an external site) — accessed 22 October 2026
Eli Lilly and Company (2026). Lilly reports second-quarter 2026 financial results (Form 8-K, Exhibit 99.1, 5 August 2026). U.S. Securities and Exchange Commission (EDGAR). Report sec.gov (opens an external site) — accessed 20 October 2026
Eli Lilly and Company (2026). Lilly reports fourth-quarter 2025 financial results (Form 8-K, Exhibit 99.1, 4 February 2026). U.S. Securities and Exchange Commission (EDGAR). Report sec.gov (opens an external site) — accessed 20 October 2026
Junod SW (FDA History Office) (2008). FDA and Clinical Drug Trials: A Short History. U.S. Food and Drug Administration; originally published in: A Quick Guide to Clinical Trials (Bioplan, 2008), pp. 25-55. Report fda.gov (opens an external site) — accessed 22 October 2026
World Health Organization (2010). WHO best practices for injections and related procedures toolkit (WHO/EHT/10.02). World Health Organization, Geneva. Report who.int (opens an external site) — accessed 20 October 2026
World Health Organization, INN Programme (2014). International Nonproprietary Names (INN) for biological and biotechnological substances (a review), WHO/EMP/RHT/TSN/2014.1. World Health Organization. Report who.int (opens an external site) — accessed 22 October 2026
Zorginstituut Nederland (2024). Farmacotherapeutisch rapport semaglutide (Wegovy®) bij de behandeling van gewichtsbeheersing bij obesitas of overgewicht in combinatie met een comorbiditeit. Report farmacotherapeutischkompas.nl (opens an external site) — accessed 20 October 2026

Dataset (61)

ClinicalTrials.gov (2026). ClinicalTrials.gov search, intervention 'ipamorelin', 22 October 2026. Dataset clinicaltrials.gov (opens an external site) — accessed 22 October 2026
ClinicalTrials.gov (2026). ClinicalTrials.gov search, 22 October 2026: thymalfasin or thymosin alpha 1, recruiting, not yet recruiting or active. Dataset clinicaltrials.gov (opens an external site) — accessed 22 October 2026
EMBL-EBI (2026). ChEMBL compound report card: CHEMBL4297358 (BPC-157). ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 20 October 2026
EMBL-EBI (2026). ChEMBL compound report card: CHEMBL58547 (IPAMORELIN). ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 22 October 2026
EMBL-EBI (2026). ChEMBL compound CHEMBL5095485 (retatrutide): mechanisms of action. ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 20 October 2026
EMBL-EBI (2026). ChEMBL compound CHEMBL2108724 (semaglutide): mechanism of action — glucagon-like peptide 1 receptor agonist. ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 20 October 2026
EMBL-EBI (2026). ChEMBL compound report cards: CHEMBL4594313 (timbetasin) and CHEMBL4594314 (timbetasin acetate). ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 20 October 2026
EMBL-EBI (2026). ChEMBL compound CHEMBL4297839 (tirzepatide). ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 20 October 2026
European Bioinformatics Institute (EMBL-EBI) (2026). ChEMBL compound report card: CHEMBL2070241 (bremelanotide). ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 22 October 2026
European Bioinformatics Institute (EMBL-EBI) (2026). ChEMBL compound report card: CHEMBL1237026 (tesamorelin). ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 22 October 2026
European Medicines Agency (2026). Medicines data download (JSON report of all EPARs: authorised, refused, withdrawn and suspended medicines). Dataset ema.europa.eu (opens an external site) — accessed 20 October 2026
European Medicines Agency (2026). Orphan designations data download (JSON report of all EU orphan designations). Dataset ema.europa.eu (opens an external site) — accessed 20 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 118984375, Insulin Human. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 448601, Octreotide. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 137319706, Orforglipron. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 9941957, BPC-157. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 91971820 (CJC-1295). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 56841945 (tetrasubstituted GRF(1-29) amide, the peptide sold as 'CJC-1295 without DAC'). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 9831659, Ipamorelin. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 125672, Lys-Pro-Val (alpha-MSH (11-13)). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 9941379, Bremelanotide. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 92432, Melanotan II. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 171390338 (compound title 'Triple G'; deposited substances named retatrutide map here). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 171934787 (record titled 'Retatrutide (sodium salt)'). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 56843331, Semaglutide. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 146675088, MOTS-c. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 219042, Epitalon. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 9811102, Semax. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 11765600, Selank. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 16130571, Thymalfasin. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 71587328, Prezatide copper (GHK-Cu, copper tripeptide-1). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 71300630, AOD-9604. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 6918297, Hexarelin (examorelin). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 11764719, Elamipretide (SS-31). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summaries: CID 5892 (NAD+, nadide), CID 439924 (nicotinamide riboside), CID 14180 (nicotinamide mononucleotide). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 62707662 (TB-500; Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH). PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 16137828, Tesamorelin. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 166567236, Tirzepatide. PubChem. Dataset pubchem.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Library of Medicine (2026). PubMed search, 20 October 2026: ("BPC 157"[tiab] OR "BPC-157"[tiab] OR "BPC157"[tiab] OR "PL 14736"[tiab] OR "PL-14736"[tiab] OR "bepecin"[tiab] OR "BPC 157"[nm]) — 235 records, 175 with Sikiric P as author. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Library of Medicine (2026). PubMed searches, 22 October 2026: ("melanotan II"[tiab] OR "melanotan-II"[tiab] OR "melanotan 2"[tiab]) NOT review[pt] — 189 records, 10 with an author from the University of Arizona group; adding the abbreviation MTII where the abstract also mentions melanocortins, MC3R, MC4R, alpha-MSH or melanotropins — 364 records, 45 with that group and about 350 that mention animals or cells; melanotan or MTII with toxicity, carcinogenicity, pregnancy or teratogenicity terms — 59 records, none a toxicity, cancer or pregnancy study of melanotan II. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Library of Medicine (2026). PubMed searches, 20 October 2026: (retatrutide[tiab] OR LY3437943[tiab]) — 207 records; AND randomized controlled trial[pt] — 10 records, 0 after NOT lilly[ad]. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
National Library of Medicine (2026). PubMed searches for MOTS-c, 22 October 2026 (record counts by type and authorship). PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Library of Medicine (2026). PubMed searches for epitalon (epithalon, Ala-Glu-Asp-Gly, AEDG), 22 October 2026 (record counts by authorship). PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Library of Medicine (2026). PubMed searches for Semax and Selank, 22 October 2026 (record counts by authorship and affiliation). PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
National Library of Medicine (2026). PubMed searches for thymosin alpha 1 (thymalfasin), 22 October 2026 (record counts). PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Library of Medicine (2026). PubMed searches for GHK-Cu, 23 October 2026. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Library of Medicine (2026). PubMed search for AOD-9604, 23 October 2026. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Library of Medicine (2026). PubMed searches for hexarelin, 23 October 2026. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Library of Medicine (2026). PubMed searches for elamipretide / SS-31, 23 October 2026. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Library of Medicine (2026). PubMed searches for nicotinamide riboside and nicotinamide mononucleotide, 23 October 2026. PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 23 October 2026
National Library of Medicine (2026). PubMed search, 20 October 2026: tirzepatide[tiab] AND randomized controlled trial[pt] — 134 records; 13 after excluding records with a Lilly affiliation (NOT lilly[ad]). PubMed. Dataset pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 20 October 2026
Office of the Federal Register (2026). Federal Register document search, 20 October 2026: "bulk drug substances", published from 24 July 2026 — no proposed or final rule on the 503A bulks list. Federal Register. Dataset federalregister.gov (opens an external site) — accessed 20 October 2026
Office of the Federal Register (2026). Federal Register document search for 'CJC-1295', 22 October 2026: no proposed or final rule. Federal Register. Dataset federalregister.gov (opens an external site) — accessed 22 October 2026
Office of the Federal Register (2026). Federal Register document search for 'ipamorelin', 22 October 2026: no proposed or final rule. Federal Register. Dataset federalregister.gov (opens an external site) — accessed 22 October 2026
Office of the Federal Register (2026). Federal Register document search, 22 October 2026: FDA documents since 24 July 2026 on compounding, '503A', '503B' and the Pharmacy Compounding Advisory Committee. Federal Register. Dataset federalregister.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). openFDA Drugs@FDA queries, 22 October 2026: selank, semax, epitalon, MOTS-c, thymalfasin, thymosin. openFDA. Dataset api.fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (2026). GRAS Notice Inventory searches, 23 October 2026: AOD-9604, 9604, nicotinamide mononucleotide, nicotinamide riboside, copper. FDA Human Foods Program. Dataset hfpappexternal.fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (2026). openFDA Drugs@FDA queries, 23 October 2026: prezatide, GHK, copper tripeptide, AOD-9604, AOD9604, hexarelin, examorelin, nicotinamide riboside, nicotinamide mononucleotide, nadide, nicotinamide adenine dinucleotide, elamipretide. openFDA. Dataset api.fda.gov (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration / NCATS (2026). Global Substance Registration System: CJC-1295 (UNII 62RC32V9N7). GSRS. Dataset gsrs.ncats.nih.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration / NCATS (2026). Global Substance Registration System: retatrutide (UNII NOP2Y096GV). GSRS. Dataset gsrs.ncats.nih.gov (opens an external site) — accessed 20 October 2026
U.S. Food and Drug Administration, Global Substance Registration System (2026). GSRS substance record: L-lysyl-L-prolyl-L-valine, UNII 7V6LGD8S5R. FDA Global Substance Registration System. Dataset gsrs.ncats.nih.gov (opens an external site) — accessed 20 October 2026

Book chapter (1)

Brzoska T, Böhm M, Lügering A, Loser K, Luger TA (2010). Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Advances in Experimental Medicine and Biology 681:107-116. Book chapter doi:10.1007/978-1-4419-6354-3_8 (opens an external site)

Web page (80)

Apotheek.nl (KNMP, Royal Dutch Pharmacists Association) (2025). Medicijnafval: niet weggooien, maar inleveren. Web page apotheek.nl (opens an external site) — accessed 20 October 2026
Apotheek.nl (KNMP, Royal Dutch Pharmacists Association) (2025). Nadroparine. Web page apotheek.nl (opens an external site) — accessed 20 October 2026
Bijwerkingencentrum Lareb (2021). Risico's illegale geneesmiddelen (Medicijnjournaal december 2021). Web page lareb.nl (opens an external site) — accessed 22 October 2026
Bijwerkingencentrum Lareb (2026). Alles over bijwerkingen melden. Web page lareb.nl (opens an external site) — accessed 20 October 2026
Bijwerkingencentrum Lareb (2026). Netherlands Pharmacovigilance Centre Lareb — report a side effect. Web page lareb.nl (opens an external site) — accessed 20 October 2026
Dopingautoriteit (2026). Controles in België. Web page dopingautoriteit.nl (opens an external site) — accessed 22 October 2026
Dopingautoriteit (2026). Eigen Kracht (programme for the fitness sector). Web page dopingautoriteit.nl (opens an external site) — accessed 22 October 2026
Dopingautoriteit (2026). Positieve dopingtest. Web page dopingautoriteit.nl (opens an external site) — accessed 22 October 2026
Dopingautoriteit (2026). WADA publiceert Dopinglijst 2027. Web page dopingautoriteit.nl (opens an external site) — accessed 22 October 2026
Dopingautoriteit (Doping Authority Netherlands) (2025). Pim de Ronde benoemd tot hoogleraar doping en gezondheid aan VU Amsterdam. Web page dopingautoriteit.nl (opens an external site) — accessed 22 October 2026
Dopingautoriteit (Doping Authority Netherlands) (2026). Doping en de wet. Web page dopingautoriteit.nl (opens an external site) — accessed 22 October 2026
KNMG (Royal Dutch Medical Association) (2024). Medisch beroepsgeheim: wat en waarom. Web page knmg.nl (opens an external site) — accessed 20 October 2026
KNMG (Royal Dutch Medical Association) (2026). Medisch beroepsgeheim: wanneer doorbreken. Web page knmg.nl (opens an external site) — accessed 22 October 2026
KNMG Artseninfolijn (2024). Heeft mijn patiënt recht op een verwijzing voor een second opinion?. Web page knmg.nl (opens an external site) — accessed 22 October 2026
Meadows M (FDA Consumer magazine) (2006). Promoting Safe and Effective Drugs for 100 Years. FDA Consumer magazine, Centennial Edition, January–February 2006 (fda.gov). Web page fda.gov (opens an external site) — accessed 22 October 2026
Medicines and Healthcare products Regulatory Agency (2026). Yellow Card: making medicines and medical devices safer. Web page yellowcard.mhra.gov.uk (opens an external site) — accessed 22 October 2026
MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine) (2025). Rhabdomyolysis. Web page medlineplus.gov (opens an external site) — accessed 20 October 2026
MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine) (2025). Malignant hypertension. Web page medlineplus.gov (opens an external site) — accessed 20 October 2026
MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine) (2025). Lymphangitis. Web page medlineplus.gov (opens an external site) — accessed 20 October 2026
MedlinePlus, U.S. National Library of Medicine (2023). Liver Function Tests. Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
MedlinePlus, U.S. National Library of Medicine (2024). Complete Blood Count (CBC). Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
MedlinePlus, U.S. National Library of Medicine (2024). IGF-1 (Insulin-Like Growth Factor-1) Test. Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
MedlinePlus, U.S. National Library of Medicine (2024). Cholesterol Levels. Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
MedlinePlus, U.S. National Library of Medicine (2025). Hemoglobin A1C (HbA1c) Test. Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
MedlinePlus, U.S. National Library of Medicine (2026). Glomerular Filtration Rate (GFR) Test. Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
NADO Vlaanderen (Dopinglijn) (2026). Regelgeving. Web page dopinglijn.be (opens an external site) — accessed 22 October 2026
Nationaal Vergiftigingen Informatie Centrum (NVIC), UMC Utrecht (2026). Nationaal Vergiftigingen Informatie Centrum. Web page nvic.umcutrecht.nl (opens an external site) — accessed 22 October 2026
National Human Genome Research Institute (NIH) (2026). Peptide — Talking Glossary of Genomic and Genetic Terms. Web page genome.gov (opens an external site) — accessed 22 October 2026
National Human Genome Research Institute (NIH) (2026). Amino Acids — Talking Glossary of Genomic and Genetic Terms. Web page genome.gov (opens an external site) — accessed 22 October 2026
National Institute of Standards and Technology (NIST) (2026). National Voluntary Laboratory Accreditation Program (NVLAP). Web page nist.gov (opens an external site) — accessed 22 October 2026
Nederlands Huisartsen Genootschap (Thuisarts.nl) (2025). Ik wil misschien laten onderzoeken of ik wel gezond ben. Web page thuisarts.nl (opens an external site) — accessed 22 October 2026
NHS (2024). Carpal tunnel syndrome. Web page nhs.uk (opens an external site) — accessed 22 October 2026
NHS (2025). Poisoning. Web page nhs.uk (opens an external site) — accessed 22 October 2026
NHS (2026). High blood sugar (hyperglycaemia). Web page nhs.uk (opens an external site) — accessed 22 October 2026
NHS (2026). Oedema (swelling). Web page nhs.uk (opens an external site) — accessed 22 October 2026
NHS (England) (2023). Boils. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2023). Anaphylaxis. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2023). Low blood sugar (hypoglycaemia). Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2023). Priapism (painful erections). Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2023). Chest pain. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2023). Moles. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2023). Diarrhoea and vomiting. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2024). High blood pressure (hypertension). Web page nhs.uk (opens an external site) — accessed 22 October 2026
NHS (England) (2024). Cellulitis. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2024). Symptoms of a stroke. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2024). Headaches. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2024). Jaundice. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2024). Shortness of breath. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2024). Anticoagulant medicines: side effects. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2025). Vision loss. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2025). Cancer. Web page nhs.uk (opens an external site) — accessed 21 October 2026
NHS (England) (2026). Skin abscess. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2026). Necrotising fasciitis. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2026). Sepsis. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2026). Acute pancreatitis. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2026). Heart palpitations. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2026). Fainting. Web page nhs.uk (opens an external site) — accessed 20 October 2026
NHS (England) (2026). Dehydration. Web page nhs.uk (opens an external site) — accessed 20 October 2026
Nobel Prize Outreach (1923). The Nobel Prize in Physiology or Medicine 1923: Summary. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026
Nobel Prize Outreach (1955). The Nobel Prize in Chemistry 1955: Summary. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026
Nobel Prize Outreach (1958). The Nobel Prize in Chemistry 1958: Summary. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026
Nobel Prize Outreach (1977). The Nobel Prize in Physiology or Medicine 1977: Summary. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026
Stichting Mainline (2023). Veilig injecteren van anabole steroïden. Web page mainline.nl (opens an external site) — accessed 20 October 2026
The Nobel Assembly at the Karolinska Institute (1977). The Nobel Prize in Physiology or Medicine 1977: Press release. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026
The Royal Swedish Academy of Sciences (1984). The Nobel Prize in Chemistry 1984: Press release. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap, NHG) (2024). Ik ga naar de huisarts: wat kan ik van tevoren doen en verwachten?. Web page thuisarts.nl (opens an external site) — accessed 22 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap) (2022). Ik heb een sepsis. Web page thuisarts.nl (opens an external site) — accessed 20 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap) (2022). Ik heb onveilige seks gehad met iemand die hiv of misschien hiv heeft. Web page thuisarts.nl (opens an external site) — accessed 20 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap) (2025). Ik krijg ineens dikke ogen of lippen. Web page thuisarts.nl (opens an external site) — accessed 20 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap) (2026). Ik heb wondroos. Web page thuisarts.nl (opens an external site) — accessed 20 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap) (2026). Ik heb pijn op mijn borst. Wat kan het zijn?. Web page thuisarts.nl (opens an external site) — accessed 20 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap) (2026). Ik heb opeens een verlamde arm, verlamd been of scheve mond. Of ik praat, slik of zie opeens niet goed.. Web page thuisarts.nl (opens an external site) — accessed 20 October 2026
Thuisarts.nl (Nederlands Huisartsen Genootschap) (2026). Ik ga insuline spuiten bij diabetes type 2. Web page thuisarts.nl (opens an external site) — accessed 20 October 2026
Tiselius A (Nobel Committee for Chemistry, Royal Swedish Academy of Sciences) (1958). The Nobel Prize in Chemistry 1958: Presentation speech. NobelPrize.org. Web page nobelprize.org (opens an external site) — accessed 22 October 2026
Trimbos-instituut (DRUGSinfo) (2026). Injecteren (spuiten/slammen): risico's verminderen. Web page drugsinfo.nl (opens an external site) — accessed 20 October 2026
U.S. Anti-Doping Agency (2026). IV Infusions: Explanatory Note. Web page usada.org (opens an external site) — accessed 23 October 2026
U.S. Food and Drug Administration (photograph and description), via Wikimedia Commons (2012). President Kennedy & Frances O. Kelsey (FDA 172). Web page commons.wikimedia.org (opens an external site) — accessed 22 October 2026
U.S. National Library of Medicine (2026). About PubMed. Web page pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
UK Anti-Doping (2026). Athletes – Rights and Responsibilities. Web page ukad.org.uk (opens an external site) — accessed 22 October 2026
UK Anti-Doping (2026). 2027 Prohibited List: Summary of Changes. Web page ukad.org.uk (opens an external site) — accessed 22 October 2026

Image credits

Every image on this site: what it shows, who made it, and the licence under which we use it. We keep all image files on our own server, so viewing them sends nothing to anyone else. (76 images)

AI-generated illustrations contain no text, numbers or labels. Every label you see on them is added by us as real text, so it can be translated and read aloud. A person checks each one for scientific errors before it is used.

Photo. Fat tissue under a microscope: many large, empty-looking round cells with thin purple walls.
Caption
Fat tissue under the microscope. AOD-9604 helped obese rodents lose fat; in people, weight loss was not shown.

Made by
Berkshire Community College Bioscience Image Library, Connective Tissues: Adipose

Original title
Connective Tissues Adipose (26915768267)

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 23 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 142:5182-5189. Research article doi:10.1210/endo.142.12.8522 (opens an external site)
U.S. Food and Drug Administration (2024). FDA Briefing Document: Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate) for Inclusion on the 503A Bulk Drug Substances List, Pharmacy Compounding Advisory Committee, 4 December 2024. Regulator fda.gov (opens an external site) — accessed 23 October 2026
Photo. Fat tissue under a microscope: large, pale, many-sided fat cells with thin pink walls, packed tightly together.
Caption
Fat cells under a microscope. In trials, tesamorelin shrank deep belly fat, but only while it was used.

Made by
Berkshire Community College Bioscience Image Library, Berkshire Community College Bioscience Image Library

Original title
Connective Tissue Adipose (41066513194)

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine 357:2359-2370. Clinical trial doi:10.1056/NEJMoa072375 (opens an external site)
U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2026). EGRIFTA SV (tesamorelin for injection): prescribing information and instructions for use. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 20 October 2026
Photo. A yellow Dutch ambulance with blue and red stripes and the Dutch emergency number on its side, parked outside an ambulance station.
Caption
A Dutch ambulance in the Haaglanden region. When a life is in danger, call your local emergency number.

Made by
Alf van Beem

Original title
Ambulance Haaglanden unit 15-114, Mercedes at Delft, The Netherlands pic1

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Rijksoverheid (Government of the Netherlands) (2026). Wat moet ik doen als iemand dringend medische hulp nodig heeft?. Regulator rijksoverheid.nl (opens an external site) — accessed 20 October 2026
European Commission (2026). 112: the European emergency number. Regulator digital-strategy.ec.europa.eu (opens an external site) — accessed 20 October 2026
Photo. Long, flat crystals in yellow, orange and blue on a pink background, seen through a microscope.

Caption
Crystals of amino acids on a glass slide. The photo was taken through a microscope with polarised light.

Made by
Aw1792300

Original title
Recrystallized Amino acid birefringence artwork

Licence

CC BY 4.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A thin slice of gland tissue under a microscope. Round cells stained pink, purple or pale blue lie close together, each with a dark centre.
Caption
The front part of the pituitary gland, a small gland under the brain. Growth hormone is made here.

Made by
Mikael Häggström, M.D.

Original title
Histology of pars distalis of the anterior pituitary with chromophobes, basophils, and acidophils

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
de Sousa LMM, Vicente VAN, Donato J (2025). Negative Feedback Loops and Hormonal Factors that Regulate GH Secretion. Endocrinology 166:bqaf139. Review doi:10.1210/endocr/bqaf139 (opens an external site)
Photo. The start of a red running track, with white lines and the lane numbers 1, 2 and 3 painted on it.

Caption
Lanes on an athletics track.

Made by
Santeri Viinamäki

Original title
Athletics track start line numbers 1, 2, 3

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A round lab dish split into a clear half and a red half, with creamy white bacterial colonies growing across both.

Caption
Colonies of bacteria grown on a lab dish.

Made by
CDC / Dr. James Feeley, Centers for Disease Control and Prevention (CDC)

Original title
Blood agar and bicarbonate agar plate cultures of Bacillus cereus

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Close-up of a plastic molecule model: red, black, blue and white balls joined by thin metal rods.

Caption
A ball-and-stick model. Each ball is an atom, and each rod is a chemical bond.

Made by
Paul Hudson from United Kingdom, Molecule

Original title
Molecule (1)

Licence

CC BY 2.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Two young men in suits sit side by side in an office, in front of a bookcase. A black-and-white photo.
Caption
Best (left) and Banting, about 1924. Their team first gave insulin to people with diabetes in 1922.

Made by
Unknown author

Original title
C. H. Best and F. G. Banting ca. 1924

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922). Pancreatic Extracts in the Treatment of Diabetes Mellitus. Canadian Medical Association Journal 12:141-146. Research article PMID 20314060 (opens an external site)
U.S. Food and Drug Administration (FDA History Office) (2022). 100 Years of Insulin. Regulator fda.gov (opens an external site) — accessed 22 October 2026
Photo. A pale stone building with tall columns, a carved front and two flags, behind a neat garden.

Caption
Brussels: the house where the Belgian lawmakers meet.

Made by
Oakenchips

Original title
Palais de la Nation Bruxelles

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A small tube of blood stands in a round holder inside a grey laboratory machine.
Caption
A blood sample waits in a lab machine. Blood tests show how some organs are doing.

Made by
U.S. Air Force photo by Airman 1st Class David S. Calcote, U.S. Air Force

Original title
374 MDG enhances operational readiness at Yokota (9003485)

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
MedlinePlus, U.S. National Library of Medicine (2023). Liver Function Tests. Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
MedlinePlus, U.S. National Library of Medicine (2026). Glomerular Filtration Rate (GFR) Test. Web page medlineplus.gov (opens an external site) — accessed 22 October 2026
Photo. An old open book with one page lifting as it turns, and a magnifying glass lying beside it.

Caption
An old book and a magnifying glass. We check each claim against its source.

Made by
Pics_Pd

Original title
Antique book page turning

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Heart muscle under a microscope: long pink fibres with dark purple cell nuclei.
Caption
Heart muscle under the microscope. In rat hearts, hexarelin attached to CD36, a protein on heart cells.

Made by
Berkshire Community College Bioscience Image Library, Muscle Tissue: Cardiac Muscle

Original title
Muscle Tissue Cardiac Muscle (28184529378)

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 23 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H (2002). CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research 90:844-849. Research article doi:10.1161/01.res.0000016164.02525.b4 (opens an external site)
Photo. Two hands held under a running tap over a steel sink. The person wears a white protective gown; no face is shown.
Caption
Washing hands under running water. Clean hands are the first step before any injection.

Made by
CDC, Kimberly Smith, Christine Ford, Centers for Disease Control and Prevention (CDC)

Original title
Person washing hands

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
World Health Organization (2010). WHO best practices for injections and related procedures toolkit (WHO/EHT/10.02). World Health Organization, Geneva. Report who.int (opens an external site) — accessed 20 October 2026
Photo. A coin spinning in the air above a hand with the thumb raised, against a green background.
Caption
A coin toss. In a small study, chance alone can make a treatment look as if it works.

Made by
ICMA Photos, Coin Toss

Original title
Coin Toss (3635981474)

Licence

CC BY-SA 2.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR (2013). Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 14:365-376. Review doi:10.1038/nrn3475 (opens an external site)
Photo. A closed wooden door in a clinic corridor with a small sign that reads Consulting Room 5.

Made by
Beendy234

Original title
Consultation room

Licence

CC BY 4.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. A cut through healthy skin seen from the side: the skin on top, a yellow fat layer with a lymph vessel and a blood vessel, and muscle below.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 21 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. The same cut through healthy skin on a dark background: skin, a fat layer with a lymph vessel and a blood vessel, and muscle below.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 21 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A thin slice of gut wall under a microscope, stained purple and pink. Many finger-like folds point outwards from a curved base.
Caption
The lining of the upper small intestine. Some cells here release the hormone GIP after a meal.

Made by
CoRus13

Original title
Duodenal biopsy, low mag

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism 18:3-14. Research article doi:10.1016/j.molmet.2018.09.009 (opens an external site)
Photo. Skin under a microscope, stained pink and purple: a thin top layer with brown pigment along its base, and small clusters of pigment cells just below it.
Caption
An abnormal mole under a microscope. Melanotan II darkens moles. Its link to skin cancer is unknown.

Made by
Nephron

Original title
Dysplastic nevus - intermed mag

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Burian EA, Jemec GBE (2019). Eruptive Melanocytic Nevi: A Review. American Journal of Clinical Dermatology 20:669-682. Review doi:10.1007/s40257-019-00444-8 (opens an external site)
Habbema L, Halk AB, Neumann M, Bergman W (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology 56:975-980. Review doi:10.1111/ijd.13585 (opens an external site)
Photo. A tall office tower with a grid of dark windows under a blue sky, with a metal sculpture by the entrance.

Caption
The EU's medicines agency has its home in this tower in Amsterdam.

Made by
MrAronymous

Original title
Zuidas Vivaldi 16

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Cells under a microscope on a black background, with blue round centres, green threads and small orange specks.

Caption
Cells from the lining of a cow's blood vessel, stained with dyes. Each cell's centre is blue.

Made by
Erin Rod

Original title
Bovine Pulmonary Artery Endothelial Cells Fluorescent Image

Licence

CC BY 4.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A yellowed page from an old book with a printed list of page and line numbers, each mistake, and its correction.

Caption
An errata page in an old book: a printed list of the printer's mistakes and their corrections.

Made by
Rodak

Original title
Errata2pl1793

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A man in a white shirt reaches up to a lamp in a laboratory full of glass flasks, bottles and racks of test tubes.

Caption
An FDA scientist checks for impurities in the 1960s. The FDA is the US medicines regulator.

Made by
The U.S. Food and Drug Administration, U.S. Food and Drug Administration

Original title
Testing Safety of Coal-Tar Colors (FDA 069) (8249291875)

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A modern office and laboratory building with a glass front and long rows of windows, under a clear blue sky.

Caption
An FDA lab building in the state of Maryland, in the US.

Made by
The U.S. Food and Drug Administration, FDA Bldg 62 - Exterior

Original title
FDA Bldg 62 - Exterior (5161375340)

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Three cells on a black background under a microscope. Fine red threads fill each cell, with a blue centre and small green worm-like shapes.
Caption
Mouse cells with their actin threads stained red. Thymosin beta-4 holds single actin units inside cells.

Made by
D. Burnette, J. Lippincott-Schwartz, NICHD (Eunice Kennedy Shriver National Institute of Child Health and Human Development), via Flickr

Original title
Cells with nuclei in blue, mitochondria in green, and the actin cytoskeleton in red (19124186316)

Licence

CC BY 2.0

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Safer D, Elzinga M, Nachmias VT (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry 266:4029-4032. Research article PMID 1999398 (opens an external site)
Photo. A row of national flags on tall poles in front of a round glass building, with the sun behind clouds.

Caption
A row of flags in front of the EU parliament in Strasbourg, France.

Made by
Syced

Original title
December 2007, flags in front of Louise Weiss building 2

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. The lining of the stomach under a microscope, stained pink and purple, with deep folds and tightly packed gland cells.
Caption
The lining of the stomach under a microscope. Its cells release pepsin, an enzyme that cuts protein.

Made by
Nephron

Original title
Normal gastric mucosa intermed mag

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J (2021). Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharmaceutica Sinica B 11:2416-2448. Review doi:10.1016/j.apsb.2021.04.001 (opens an external site)
Photo. A Gila monster, a heavy lizard with beaded black and orange-pink skin, walking over red rocks and dry grass at night.
Caption
A Gila monster. Its venom led to a drug that works like semaglutide, which copies a human hormone.

Made by
Jeff Servoss, U.S. Fish and Wildlife Service

Original title
Reticulate Gila Monster

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Journal of Biological Chemistry 267:7402-7405. Research article doi:10.1016/S0021-9258(18)42531-8 (opens an external site)
Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 30:72-130. Review doi:10.1016/j.molmet.2019.09.010 (opens an external site)
European Medicines Agency (2026). Wegovy (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu (opens an external site) — accessed 20 October 2026
AI-generated illustration. Four separate organs on a plain background: a brain seen from the side at the top, a blood vessel across the middle, a pancreas at the bottom left and a stomach at the bottom right.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 20 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. The same four organs on a dark background: a brain seen from the side, a blood vessel across the middle, a pancreas and a stomach.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 20 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. Drawing of the front of a human head and trunk, down to the hips. The brain, the stomach and the pancreas behind it are in colour; the body is a faint outline.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 20 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. The same drawing on a dark background: the front of a head and trunk with the brain, the stomach and the pancreas in colour.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 20 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Illustration. A black line drawing of two hands shaking, on a white background.
Caption
A handshake. Studies paid for by the maker more often find good results for its product.

Made by
Aidan Jones, Handshake

Original title
Handshake (3575000735)

Licence

CC BY-SA 2.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2:MR000033. Review doi:10.1002/14651858.MR000033.pub3 (opens an external site)
Photo. A black-and-white hooded laboratory rat with long whiskers, standing in the corner of a white box.
Caption
A hooded lab rat. Few of the things that help in animals become medicines for people.

Made by
Benmitch

Original title
Whiskers of the Hooded Lister Rat ATLAS-070713-0016

Licence

CC BY 3.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Ineichen BV, Furrer E, Grüninger SL, Zürrer WE, Macleod MR (2024). Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biology 22:e3002667. Research article doi:10.1371/journal.pbio.3002667 (opens an external site)
Photo. The glass entrance of a modern Dutch health building under a large overhanging floor, with a tree and a paved square in front.
Caption
A GP post for evenings, nights and weekends (huisartsenpost) in the Dutch town of Oss.

Made by
RagingR2

Original title
Huisartsenpost Oss jun 2023

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Rijksoverheid (Government of the Netherlands) (2026). Wat moet ik doen als iemand dringend medische hulp nodig heeft?. Regulator rijksoverheid.nl (opens an external site) — accessed 20 October 2026
Photo. Half of a preserved human brain, cut down the middle, in a clear box of fluid. The folds, the brainstem and the cerebellum at the back show.
Caption
From a teaching collection. PT-141 acts on receptors in the brain. How it changes desire is not known.

Made by
Themium

Original title
Human brain, sagittal section 1

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2025). VYLEESI (bremelanotide injection): prescribing information. Official product information dailymed.nlm.nih.gov (opens an external site) — accessed 20 October 2026
Photo. A thin slice of pancreas under a microscope. A round cluster of cells stained dark blue, edged with red cells, sits in pale pink tissue.
Caption
Cells in a human pancreas. Red cells make glucagon. Blue cells make insulin. Retatrutide also acts on the glucagon receptor.

Made by
Afferent

Original title
Human pancreatic islet

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism 34:1234-1247.e9. Research article doi:10.1016/j.cmet.2022.07.013 (opens an external site)
EMBL-EBI (2026). ChEMBL compound CHEMBL5095485 (retatrutide): mechanisms of action. ChEMBL. Dataset ebi.ac.uk (opens an external site) — accessed 20 October 2026
Illustration. Computer model of the blood protein albumin: green spiral ribbons, with small orange chains of fat held inside it.
Caption
Albumin, a blood protein. The original CJC-1295 was built to bond to it and last for days.

Made by
Deposition authors: Bhattacharya, A.A., Gruene, T., Curry, S.; visualization author: User:Astrojan

Original title
1e7h

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146:3052-3058. Research article doi:10.1210/en.2004-1286 (opens an external site)
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism 91:799-805. Clinical trial doi:10.1210/jc.2005-1536 (opens an external site)
AI-generated illustration. Separate organs on a plain background: a brain at the top, a liver, a short blood vessel and a stomach in the middle, a pancreas and a block of fat below.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 21 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. The same separate organs on a dark background: a brain, a liver, a short blood vessel, a stomach, a pancreas and a block of fat.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 21 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Clear crystals with many flat sides, some stacked together, on a pale blue background under a microscope.

Caption
Insulin crystals, seen up close. The photo comes from NASA.

Made by
NASA/Marshall, NASA Marshall Space Flight Center (photo ID 9901879)

Original title
Insulincrystals

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 21 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A black-and-white photo of President John F. Kennedy handing a pen to Frances Kelsey, with men in suits watching.
Caption
In 1962, President Kennedy hands a pen to Frances Kelsey. At the FDA she said no to thalidomide.

Made by
U.S. Food and Drug Administration

Original title
President Kennedy & Frances O. Kelsey (FDA 172) (8212346106)

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. Food and Drug Administration (2018). Frances Oldham Kelsey: Medical reviewer famous for averting a public health tragedy. Regulator fda.gov (opens an external site) — accessed 22 October 2026
U.S. Food and Drug Administration (photograph and description), via Wikimedia Commons (2012). President Kennedy & Frances O. Kelsey (FDA 172). Web page commons.wikimedia.org (opens an external site) — accessed 22 October 2026
Photo. President Kennedy sits at his desk and hands a pen to a senator. Men in suits and one woman stand around him.
Caption
President Kennedy after signing a new drug law in 1962. Now medicines had to show they work.

Made by
Abbie Rowe, John F. Kennedy Presidential Library and Museum

Original title
President Signing the 1962 Drug Amendments

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
United States Congress (1962). Public Law 87-781 (Drug Amendments of 1962), 76 Stat. 780, approved 10 October 1962. United States Statutes at Large, volume 76. Law govinfo.gov (opens an external site) — accessed 22 October 2026
Meadows M (FDA Consumer magazine) (2006). Promoting Safe and Effective Drugs for 100 Years. FDA Consumer magazine, Centennial Edition, January–February 2006 (fda.gov). Web page fda.gov (opens an external site) — accessed 22 October 2026
Photo. A pipette with eight thin tips puts pink liquid into a plastic plate with many small wells.

Caption
Lab research: a liquid goes into a test plate with many small wells.

Made by
J.N. Eskra

Original title
96 well plate

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A small brown laboratory mouse sitting on the palm of a hand in a blue disposable glove.
Caption
A laboratory mouse. KPV research so far is in cells and animals. No study in people is published.

Made by
Rama

Original title
Lab mouse mg 3263

Licence

CC BY-SA 2.0 FR Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. Food and Drug Administration (2026). FDA Briefing Document for KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate), Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026
Photo. Shelves full of old law books with brown leather spines and small library labels.

Caption
Old law books in a court library.

Made by
Dominic

Original title
Indiana Supreme Court Law Library rare books shelf

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Colourised electron microscope image of a round, bumpy immune cell in green, with long thin arms, on a brown background.
Caption
An immune cell that eats germs. Selank is built on tuftsin, which stirs up such cells.

Made by
NIAID, National Institute of Allergy and Infectious Diseases

Original title
Macrophage (17195150690)

Licence

CC BY 2.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Fridkin M, Najjar VA (1989). Tuftsin: its chemistry, biology, and clinical potential. Critical Reviews in Biochemistry and Molecular Biology 24:1-40. Review doi:10.3109/10409238909082550 (opens an external site)
Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N (2011). Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides 170:18-23. Research article doi:10.1016/j.regpep.2011.05.001 (opens an external site)
Photo. A gloved hand puts a small sample into a tray of wells on a large laboratory machine full of tubes and wires.
Caption
Samples go into a mass spectrometer at the US regulator. It can show what is in a sample.

Made by
The U.S. Food and Drug Administration, U.S. Food and Drug Administration

Original title
FDA Center for Food Safety & Applied Nutrition (CFSAN) 6486 (8755007149)

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
European Medicines Agency, CHMP and CVMP (2025). Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). European Medicines Agency. Regulator ema.europa.eu (opens an external site) — accessed 22 October 2026
Photo. Black-and-white electron microscope image of two oval mitochondria with folded inner walls, inside a lung cell.
Caption
Two mitochondria, the energy parts of a cell. MOTS-c is made from their own small set of genes.

Made by
Louisa Howard

Original title
Mitochondria, mammalian lung - TEM

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 21:443-454. Research article doi:10.1016/j.cmet.2015.02.009 (opens an external site)
AI-generated illustration. A block of muscle on a plain background. The cut end shows bundles of muscle fibres; long fibres run along its length.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 22 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. The same block of muscle on a dark background, with bundles of fibres on its cut end and long fibres along its length.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 22 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A large library reading room with wooden tables, chairs and low bookshelves, and computer desks further back.
Caption
The main reading room of the US National Library of Medicine in 2008. The library runs PubMed.

Made by
Sage Ross

Original title
National Library of Medicine, Main Reading Room, October 9, 2008

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. National Library of Medicine (2026). About PubMed. Web page pubmed.ncbi.nlm.nih.gov (opens an external site) — accessed 22 October 2026
AI-generated illustration. A simple line drawing of a small clear glass vial with a grey rubber stopper and a little white powder at the bottom, on a light grey background. It has no label.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 21 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
AI-generated illustration. The same line drawing of a small clear glass vial with a grey rubber stopper and a little white powder at the bottom, on a near-black background. It has no label.

Made by
AI-generated with gpt-image-2.5-sunburst-2026-09-08 for Peptides Explained

Licence

CC BY 4.0

AI-generated illustration

Generated with gpt-image-2.5-sunburst-2026-09-08 on 21 October 2026. Checked for scientific errors

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A long gothic palace with towers and a clock tower, lit up at dusk and reflected in a river.

Caption
The Palace of Westminster in London. The UK Parliament meets here.

Made by
Diliff

Original title
Palace of Westminster, London - Feb 2007

Licence

CC BY-SA 2.5 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. An old balance with two empty metal pans hanging from a gold-coloured stand on a wooden box with two drawers.

Made by
HelgeRieder

Original title
Apothekenwaage Rezepturwaage (2)

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. An old brass mortar with two handles and a heavy brass pestle standing in it.
Caption
An old mortar from a pharmacy. A pharmacy may still make some medicines itself.

Made by
Lupus in Saxonia

Original title
Antique brass pharmacy mortar weighing 2.3 kg - Picture 1

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Inspectie Gezondheidszorg en Jeugd (IGJ) (2025). Eigen bereidingen apotheek. Regulator igj.nl (opens an external site) — accessed 22 October 2026
Photo. Pink and purple stained tissue under a microscope: tightly packed cells of the pineal gland with small blood vessels between them.
Caption
This gland makes the sleep hormone melatonin. Epitalon was based on an extract of it from cattle.

Made by
Nephron

Original title
Pineal gland - intermed mag

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. Food and Drug Administration (2026). FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 22 October 2026
Illustration. A computer drawing of part of a protein on a black background: thin blue sticks for the chain and clouds of coloured dots around it.

Caption
A computer model of part of a protein. Scientists draw molecules like this to see their shape.

Made by
CSIRO, CSIRO ScienceImage

Original title
CSIRO ScienceImage 1788 Molecular model of a protein

Licence

CC BY 3.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Microscope image of a rat brain slice in blue, green and gold. Curved gold bands of tightly packed cell nuclei trace the layers of the hippocampus.
Caption
The hippocampus of a rat. In rats, Semax raised a growth factor for nerve cells in this area.

Made by
NIH Image Gallery from Bethesda, Maryland, USA, National Institutes of Health

Original title
Rat Hippocampus (29414539952)

Licence

CC BY 2.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research 1117:54-60. Research article doi:10.1016/j.brainres.2006.07.108 (opens an external site)
Photo. A large stone building with columns, four corner towers and a glass dome, with German flags, in evening light.

Caption
The Reichstag in Berlin. The German parliament meets here.

Made by
Jürgen Matern, Own work(JMatern_071104_8454-8458_WC.jpg)

Original title
Reichstag building Berlin view from west before sunset

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A brick medieval hall with two pointed towers and a round window, behind a wide cobbled square with a gilded fountain.

Caption
The Ridderzaal in The Hague, in the heart of the Dutch parliament buildings.

Made by
Frans Berkelaar

Original title
Ridderzaal - Binnenhof - Den Haag - NL

Licence

CC BY 2.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. A yellow plastic container with a red lid and a small flap opening on top, on a white background.
Caption
A sharps container: a hard plastic box for used needles, with a lid that closes tightly.

Made by
Nadina Wiórkiewicz (Nadine90), In cooperation with the school of photography Fotoedukacja

Original title
Sharp waste bin 2

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. Food and Drug Administration (2021). Sharps Disposal Containers. Regulator fda.gov (opens an external site) — accessed 20 October 2026
Apotheek.nl (KNMP, Royal Dutch Pharmacists Association) (2025). Medicijnafval: niet weggooien, maar inleveren. Web page apotheek.nl (opens an external site) — accessed 20 October 2026
Photo. An old wooden signpost on a green hillside, with arms pointing along different paths.

Made by
Eirian Evans, Geograph Britain and Ireland

Original title
Coast Path signpost at a crossroads - geograph.org.uk - 7016551

Licence

CC BY-SA 2.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Muscle fibres under a microscope: long pink strands with fine cross-stripes and dark nuclei along their edges.
Caption
Muscle under the microscope. A US approval covers muscle strength in one rare disease.

Made by
Berkshire Community College Bioscience Image Library, Muscle Tissue: Skeletal Muscle Fibers

Original title
Muscle Tissue Skeletal Muscle Fibers (40153601630)

Licence

CC0 1.0

Source

Original file on Wikimedia Commons , retrieved 23 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. Food and Drug Administration; Stealth BioTherapeutics Inc. (2025). FORZINITY (elamipretide) injection, for subcutaneous use: Prescribing Information (revised 9/2025). Official product information accessdata.fda.gov (opens an external site) — accessed 23 October 2026
Photo. A slice of human skin under a microscope: a thin purple outer layer above a thicker, pale pink layer of fibres, with small clusters of cells from a harmless mole deeper down.
Caption
Human skin under the microscope. Cosmetics with GHK-Cu go on the top layer; injections go below the skin.

Made by
Kilbad

Original title
Normal Epidermis and Dermis with Intradermal Nevus 10x

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 23 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
European Parliament and Council of the European Union (2009). Regulation (EC) No 1223/2009 on cosmetic products, Article 2 (definitions). Official Journal of the European Union, L 342. Law eur-lex.europa.eu (opens an external site) — accessed 23 October 2026
Photo. Two round bacteria under an electron microscope, surrounded by a web of fine threads, shown in blue-green.
Caption
Staph bacteria seen under a strong microscope. This kind of germ can cause skin infections.

Made by
Eric Erbe, Christopher Pooley, U.S. Department of Agriculture, Agricultural Research Service

Original title
Staphylococcus aureus, 50,000x, USDA, ARS, EMU

Licence

Public domain

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine) (2025). Lymphangitis. Web page medlineplus.gov (opens an external site) — accessed 20 October 2026
Photo. A stethoscope with black tubing and a silver chest piece lying on a plain grey surface.

Caption
Talk to a doctor before you start.

Made by
Jacek Halicki

Original title
2023 Stetoskop

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Three measuring scales side by side on a white surface: the end of a yellow tape measure, a pale blue tape marked in centimetres and a metal ruler, each marked differently.

Caption
Three rulers, each with its own scale. We grade evidence on four scales and never add them up.

Made by
William Warby from London, England, 3cm

Original title
3cm - Flickr - wwarby

Licence

CC BY 2.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Pink and purple stained tissue under a microscope: a large pink swirl of flattened cells surrounded by many small dark immune cells.
Caption
Tissue from the thymus, seen under a microscope. Thymosin alpha-1 was first found in calf thymus.

Made by
Nephron

Original title
Thymic corpuscle

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
U.S. Food and Drug Administration (2024). FDA Briefing Document for Thymosin Alpha-1 Related Bulk Drug Substances (Thymosin alpha-1 (free base) and Thymosin alpha-1 acetate), Pharmacy Compounding Advisory Committee meeting, 4 December 2024. Regulator fda.gov (opens an external site) — accessed 22 October 2026
Photo. An empty debating chamber with rows of wooden desks and blue chairs in a half circle, a speaker's desk and a Dutch flag.

Caption
The debating hall of the Dutch lower house in The Hague, seen in 2018.

Made by
Husky

Original title
Plenaire zaal Tweede Kamer - landschap

Licence

CC BY 4.0

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Photo. Vitamin B3 crystals under polarised light, forming blue, green and purple star-shaped patterns.
Caption
Vitamin B3 crystals in polarised light. The body makes NAD+ from NR and NMN, two forms of B3.

Made by
Andrei Savitsky

Original title
Микро кристаллы в поляризованном свете. Витамин В3

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 23 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Castenmiller J, de Henauw S, et al. (2019). Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA Journal 17:e05775. Regulator doi:10.2903/j.efsa.2019.5775 (opens an external site)
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, et al. (2026). Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC. EFSA Journal 24:e10007. Regulator doi:10.2903/j.efsa.2026.10007 (opens an external site)
Photo. A wooden hourglass standing upright, with sand running from the top glass into the bottom glass.
Caption
An hourglass. Half-life is the time it takes for half of a medicine to leave the blood.

Made by
User:S Sepp

Original title
Wooden hourglass 3

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Santiago M, Davis EA, Hinton T, Angelo TA, Shield A, Babey AM, et al. (2021). Defining and unpacking the core concepts of pharmacology education. Pharmacology Research & Perspectives 9:e00894. Research article doi:10.1002/prp2.894 (opens an external site)
Photo. A tall wooden ladder made of poles, seen from below, leaning against a pale wall in front of large green banana leaves.
Caption
A wooden ladder. Cell and animal studies are the lowest steps of the evidence ladder.

Made by
Nadinviki

Original title
WOODEN LADDER

Licence

CC BY-SA 4.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 22 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.
Caption based on
Murad MH, Asi N, Alsawas M, Alahdab F (2016). New evidence pyramid. Evidence-Based Medicine 21:125-127. Research article doi:10.1136/ebmed-2016-110401 (opens an external site)
Photo. The main building of the School of Medicine in Zagreb: a glass front that reflects an older building, above a paved square with benches and a small statue.

Caption
The main building of the medical school in Zagreb, Croatia.

Made by
Suradnik13

Original title
Medicinski fakultet Zagreb - glavni

Licence

CC BY-SA 3.0 Our cropped and tinted versions are shared under the same licence.

Source

Original file on Wikimedia Commons , retrieved 20 October 2026

Changes
Cropped and resized for the web. Some designs on this site show photos in black and white or with a colour tint.